Domain > web.insights.norstella-labs.com

More information on this domain is in AlienVault OTX

DNS Resolutions

Date	IP Address
2024-10-12	23.192.223.3 (ClassC)
2024-11-13	104.117.247.114 (ClassC)
2026-01-17	23.46.228.49 (ClassC)

HTTP/1.1 200 OKContent-Type: text/html; charsetutf-8Server: openrestyx-arc-pb-mx-id: 00000000x-arc-pb-request-id: d9a263aa-35f4-4cd3-a975-0ad62563aabfETag: W/2b5e7-ZxTAClVNb1wtEYvYZBzEb8tJFFsLast-Modified: Sat, 17 Jan 2026 18:29:18 GMTX-Akamai-Transformed: 9 33808 0 pmbmRUM,2Cache-Control: private, max-age60Expires: Sat, 17 Jan 2026 18:30:18 GMTDate: Sat, 17 Jan 2026 18:29:18 GMTTransfer-Encoding:  chunkedConnection: keep-aliveConnection: Transfer-EncodingServer-Timing: cdn-cache; descREVALIDATEServer-Timing: edge; dur438Server-Timing: origin; dur722x-arc-ttl: -1x-arc-request-id: 0.110e2017.1768674556.8bd95d95Server-Timing: ak_p; desc1768674556693_387976721_2346278293_116150_402881_7_36_-;dur1

!DOCTYPE html>html langen dirltr>head>meta nameviewport contentwidthdevice-width, initial-scale1/>link relpreconnect hrefhttps://fonts.googleapis.com/>link relpreconnect hrefhttps://fonts.gstatic.com crossorigintrue/>link relpreload asstyle hrefhttps://fonts.googleapis.com/css2?familyLexend:wght@200;300;400;500;600;700;800;900&familyPoppins&familyOpen+Sans:ital,wght@0,300..800;1,300..800&displayswap/>link hrefhttps://fonts.googleapis.com/css2?familyLexend:wght@200;300;400;500;600;700;800;900&familyPoppins&familyOpen+Sans:ital,wght@0,300..800;1,300..800&displayswap relstylesheet/>link relicon typeimage/x-icon href/pf/resources/images/favicon-insights.ico?d1572/>title>Insights/title>meta nametitle contentInsights/>meta propertyog:title contentInsights/>meta nametwitter:title contentInsights/>meta propertyog:image contenthttps://web.insights.norstella-labs.com/resizer/v2/GO6EK2X5EVAQFCOS4CEXAEZTOY.png?authc74ade46c6882d38fbec2a1c592f62c305c2c706df72dc7db9549dcb11273fca/>meta propertyog:image:alt contentInsights/>meta nametwitter:image contenthttps://web.insights.norstella-labs.com/resizer/v2/GO6EK2X5EVAQFCOS4CEXAEZTOY.png?authc74ade46c6882d38fbec2a1c592f62c305c2c706df72dc7db9549dcb11273fca/>meta nametwitter:image:alt contentInsights/>meta namemeta namedescription propertymeta namedescription contentThis is Insights home page meta description/>meta nameog:image propertyog:image contenthttps://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/XWJL7WGEH5LPBNNARY6RRNCDX4.jpg/>meta nameog:title propertyog:title contentManually set title News Context Impact/>meta propertyog:locale contenten_US/>meta propertyfb:pages content100087112443209/>meta propertyog:type contenthomepage/>meta propertyog:site_name contentInsights/>meta nametwitter:site content@Citeline/>meta nametwitter:creator content@Citeline/>meta nametwitter:card contentsummary_large_image/>link relcanonical hrefhttps://web.insights.norstella-labs.com/>script typeapplication/ld+json>{@context:https://schema.org,@type:Organization,name:Insights,url:https://web.insights.norstella-labs.com,logo:https://web.insights.norstella-labs.com/resizer/v2/GO6EK2X5EVAQFCOS4CEXAEZTOY.png?authc74ade46c6882d38fbec2a1c592f62c305c2c706df72dc7db9549dcb11273fca}/script>script typeapplication/ld+json>{@context:https://schema.org,@type:WebSite,name:Insights,url:https://web.insights.norstella-labs.com}/script>script typeapplication/ld+json>{@context:https://schema.org,@type:WebPage,name:Insights,url:https://web.insights.norstella-labs.com,isPartOf:{@type:WebSite,name:Insights,url:https://web.insights.norstella-labs.com}}/script>link idfusion-output-type-styles relstylesheet typetext/css href/pf/dist/components/output-types/default.css?d1572&mxId00000000/>link idfusion-template-styles relstylesheet typetext/css href/pf/dist/components/combinations/default.css?d1572&mxId00000000/>link idfusion-siteStyles-styles relstylesheet typetext/css href/pf/dist/css/insights.css?d1572&mxId00000000/>script typeapplication/javascript idpolyfill-script>if(!Array.prototype.includes||!(window.Object && window.Object.assign)||!window.Promise||!window.Symbol||!window.fetch){document.write(script typeapplication/javascript src/pf/dist/engine/polyfill.js?d1572&mxId00000000 defer>\/script>)}/script>script idfusion-engine-react-script typeapplication/javascript src/pf/dist/engine/react.js?d1572&mxId00000000 defer>/script>script idfusion-engine-combinations-script typeapplication/javascript src/pf/dist/components/combinations/default.js?d1572&mxId00000000 defer>/script>style>body { writing-mode: horizontal-tb; }/style>script data-integrationnewrelic srchttps://js-agent.newrelic.com/nr-loader-spa-current.min.js>/script>script data-integrationcriticalInlineScripts>    (function() {      function configureNewRelic() {        if (window.NREUM) {          window.NREUM.loader_config  {            accountID: 4394941,            trustKey: 4139912,            agentID: 1120430436,            licenseKey: NRBR-023642f2789bb6a2349,            applicationID: 1120430436          };          window.NREUM.info  {            beacon: bam.nr-data.net,            errorBeacon: bam.nr-data.net,            licenseKey: NRBR-023642f2789bb6a2349,            applicationID: 1120430436,            sa: 1          };          console.log(New Relic configured successfully);        } else {          console.warn(New Relic NREUM object not available);        }      }            // Try to configure immediately      configureNewRelic();            // If NREUM isnt available yet, wait for it      if (!window.NREUM) {        var attempts  0;        var maxAttempts  50;        var checkInterval  setInterval(function() {          attempts++;          if (window.NREUM || attempts > maxAttempts) {            clearInterval(checkInterval);            if (window.NREUM) {              configureNewRelic();            } else {              console.warn(New Relic failed to load after  + maxAttempts +  attempts);            }          }        }, 100);      }    })();  ;    (function() {      var _sf_async_config  window._sf_async_config  (window._sf_async_config || {});      _sf_async_config.uid  67118;      _sf_async_config.domain  web.insights.norstella-labs.com;      _sf_async_config.useCanonical  true;      _sf_async_config.useCanonicalDomain  true;      _sf_async_config.sections  undefined;      _sf_async_config.authors  ;    })();  ;window.isIE  !!window.MSInputMethodContext && !!document.documentMode;/script>script data-integrationnonCriticalInlineScripts>                (function() {                  var scripts  \n  const userToken  localStorage.getItem(@@auth0spajs@@::VWL5i1Egxi6dXH4Og8XD5mtGx1aZOydk::@@user@@);\n  const accessToken  localStorage.getItem(@@auth0spajs@@::VWL5i1Egxi6dXH4Og8XD5mtGx1aZOydk::https://norstella/insights/api::openid profile email address phone offline_access nxp-sso:user GNCS ROSE INV MTI PINK SCRIP);\n    \n    let isTrial_Pink  false;\n    let isTrial_Invivo  false;\n    let isTrial_Generics  false;\n    let isTrial_HBW  false;\n    let isTrial_Scrip  false;\n    let isTrial_Medtech  false;\n\n    const productCodeMap  {\n      PINK: isTrial_Pink,\n      INV: isTrial_Invivo,\n      GNCS: isTrial_Generics,\n      ROSE: isTrial_HBW,\n      SCRIP: isTrial_Scrip,\n      MTI: isTrial_Medtech\n    };\n\n\n    const tokenData  userToken ? JSON.parse(userToken) : null;\n    const accessTokenData  accessToken ? JSON.parse(\n      decodeURIComponent(\n        escape(atob(accessToken.split(\.\)1.replace(/-/g, \+\).replace(/_/g, \/\)))\n      )\n    ) : null;\n    const user   tokenData?.decodedToken?.user;\n    const trialUser  user && user?.ut;\n    const trialType  trialUser  trial;\n    const trialEntitlement  trialUser  user;\n\n    // Process the token entitlements for trial status\n    if (accessTokenData?.entls?.SF?.pcds) {\n      accessTokenData.entls.SF.pcds.forEach(pcd > {\n        if (pcd.atyp  Trial) {\n          // Set the appropriate flag based on product code\n          if (pcd.p  PINK) isTrial_Pink  true;\n          if (pcd.p  INV) isTrial_Invivo  true;\n          if (pcd.p  GNCS) isTrial_Generics  true;\n          if (pcd.p  ROSE) isTrial_HBW  true;\n          if (pcd.p  SCRIP) isTrial_Scrip  true;\n          if (pcd.p  MTI) isTrial_Medtech  true;\n        }\n      });\n    }\n    \n    // Create the visitor metadata object for trial data\n    const visitorTrialMetadata  (trialType || trialEntitlement) ? {\n      isTrial_Pink,\n      isTrial_Invivo,\n      isTrial_Generics,\n      isTrial_HBW,\n      isTrial_Scrip,\n      isTrial_Medtech\n    } : {};\n\n    const transIpData  typeof window ! undefined ? JSON.parse(localStorage.getItem(trans-ip-data) || null) : null;\n    if (user){\n      window.dataLayer  window.dataLayer || ;\n      dataLayer.push({\n        visitorId: user.userId,\n      });\n    }\n     (function(apiKey,arcSite,user){\n      (function(p,e,n,d,o){var v,w,x,y,z;opdpd||{};o._qo._q||;\n      vinitialize,identify,updateOptions,pageLoad,track;for(w0,xv.length;wx;++w)(function(m){\n          omom||function(){o._qmv0?unshift:push(m.concat(.slice.call(arguments,0)));};})(vw);\n          ye.createElement(n);y.async!0;y.srchttps://content.usageapi.citeline.com/agent/static/+apiKey+/pendo.js;\n          ze.getElementsByTagName(n)0;z.parentNode.insertBefore(y,z);})(window,document,script,pendo);\n          \n          const currentDate  new Date();\n          const dayOfWeek  currentDate.getDay();\n          const weekDay  dayOfWeek  0 || dayOfWeek  6 ? Weekend : Weekday\n          const entls  accessTokenData?.entls?.SF?.pcds || ;\n          const sectionEntl  entls.find(function(el){return el.p  undefined});\n          \n          const isCD  arcSite  cd;\n          const interestsData  isCD && typeof window ! undefined ? localStorage.getItem(Interests) : null;\n          \n          const defaultVisitor  {\n            id: user?.email || \\,\n            ...(!isCD && visitorTrialMetadata),\n            ...(isCD && interestsData ? {candUserInterests: interestsData} : {})\n          }\n\n          let visitor;\n          let subId;\n          if(user) {\n            defaultVisitor.email_address  user?.email || \\;\n\n            const cdVisitor  {\n              company_name: user?.user_metadata.company || \\, \n              candd_user_id: user?.userId || \\,\n              candd_job_title: user?.user_metadata?.job_title || \\,\n              candd_industry: user?.user_metadata?.industry || \\,\n            }\n\n            const subIdKey  sectionEntl ? `${sectionEntl.p.toLowerCase()}_subid` : subid;\n            subId  {\n              key: subIdKey,\n              value: sectionEntl?.subid\n            }\n            const insightsVisitor  {\n              subIdKey : sectionEntl?.subid,\n              user_company_name: user?.user_metadata.company || \\, \n              service_company_name: \blank\,  \n              user_entitlement_type: accessTokenData?.entls?.SF?.cnm || \\, \n              id_e_user_id: accessTokenData?.entls?.SF?.cid || \\, \n              id_e_account_id: user?.userId || \\, \n            }\n\n            visitor  arcSite  \cd\ ? cdVisitor : insightsVisitor\n          }\n\n          let product_name;\n          let entitlementPublication;\n          let product_category;\n          let page_name  \\;\n          let cdProperty;\n          if(false && false) {\n            product_name  \\; \n            product_category  \\; \n            entitlementPublication  product_name;\n\n            cdProperty  {\n              taxonomy_media_type: \\,\n              taxonomy: \\,\n            }\n          }\n          else {\n            const pathname  window.location.pathname.split(/)1;\n            const sectionsTitlesArray  generics-bulletin,hbw-insight,in-vivo,medtech-insight,pink-sheet,scrip;\n            product_name  sectionsTitlesArray.includes(pathname) ? pathname : arcSite;\n            if(arcSite  cd) {\n              product_category  window.location.pathname.split(/)1;\n              page_name  page_name ? page_name : window.location.pathname.split(/)2;\n            }\n            else {\n              product_category  \\;\n            }\n            entitlementPublication  sectionsTitlesArray.includes(pathname) ? pathname : ;\n            cdProperty  {\n              taxonomy_media_type: window.location.pathname,\n              taxonomy: product_category,\n            }\n          }\n          \n          const defaultArticleProperty  {\n            ...(subId ? {subId.key: subId.value}:{}),\n            article_id: \\,\n            headline: \\,\n            authors: \\,\n            pubdate: \\,\n            taxonomy_content_type: \\,\n            article_entitlements: \\, \n          }\n\n          if(arcSite  \insights\) {\n            defaultArticleProperty.entitlement_status  \\;\n          }\n\n          const parsedUrl  new URL(window.location.href);\n\n          if(parsedUrl.search.length > 0) {\n            const params  new URLSearchParams(parsedUrl.search);\n            for (const key, value of params.entries()) {\n              if(utm_campaign, utm_source, utm_medium, utm_content, utm_campaignID.includes(key))\n              defaultArticlePropertykey  value;\n            }\n          }\n\n          const defaultProperty  {\n              product_name: product_name,\n              page_category: product_category,\n              page_name: page_name,\n              page_referrer: document.referrer || \\,\n              page_url: document.URL || \\,\n              login_status: !!user ? \logged in\ : \logged out\,\n          }\n\n          const insightsProperty  { \n              id_e_service_id: accessTokenData?.entls?.SF?.sfcid || \\, \n              entitlement_publication: \insights.citeline.com/\ + entitlementPublication, \n              website_publication: \insights.citeline.com/\ + entitlementPublication, \n              content_entitlement_type: \\,\n              auth_type: manual\n          }\n\n          if(!user) {\n            transIpData?.entls.forEach(entl > {\n              if(entl.p  undefined && entl.atyp  Full) {\n              insightsProperty.auth_type  ip\n              }\n            });\n          }\n          \n          properties  arcSite  \cd\ ? cdProperty : insightsProperty\n          const transIpJSONData  typeof window ! undefined ? JSON.parse(localStorage.getItem(trans-ip-data) || null) : null;\n          const accountID  transIpJSONData?.id;\n          const subscriptionId  transIpJSONData?.subId;\n          const idToUse  !user ? accountID : accessTokenData?.entls?.SF?.cid || \\;\n          const subscriptionIdToUse  !user ? subscriptionId  : accessTokenData?.entls?.SF?.pcds0?.subid || \\;\n          const nameToUse  !user ? transIpJSONData?.name : user?.user_metadata.company || \\;\n           const account  trialType \n            ? { is_paying: trial }\n            : {\n                id: idToUse,\n                subscription_id: subscriptionIdToUse,\n                name: nameToUse,\n                is_paying: sectionEntl?.atyp || \\,\n                creation_date: sectionEntl?.aed || \\,\n              };\n          \n          pendo.initialize({\n            visitor: {\n              ...defaultVisitor, ...visitor\n            },\n            account,\n          });\n         \n          pendo.track(Page Info, {\n            ...(subId ? {subId.key: subId.value}:{}),\n            ...defaultProperty,\n            ...properties,\n          });\n\n          if(defaultArticleProperty.headline) {\n            pendo.track(Article Info, defaultArticleProperty);\n          }\n\n          window.subId  subId;\n    })(5cb9a88d-ec5d-479e-7993-d6721bc4b0a9, insights,  user);\n  ,\n    (function(h,o,t,j,a,r){ \n      h.hjh.hj||function(){(h.hj.qh.hj.q||).push(arguments)}; \n      h._hjSettings{hjid:5063875,hjsv:6}; ao.getElementsByTagName(head)0; \n      ro.createElement(script);r.async1; r.srct+h._hjSettings.hjid+j+h._hjSettings.hjsv; \n      a.appendChild(r); \n    })(window,document,https://static.hotjar.com/c/hotjar-,.js?sv);\n  ,\n        let oneSignalIds  {};\n\n        if (window.location.hostname.includes(cd-prod)) {\n          oneSignalIds  {\n            appId: 72c89b39-5d04-44d3-b28e-54e61f8a8fa2,\n            safariWebId: web.onesignal.auto.4dbe0dd2-36c1-4474-980b-740086f7dd0e,\n          };\n        } else if (window.location.hostname.includes(cd-sandbox)) {\n          oneSignalIds  {\n            appId: fab83cf1-911f-47a8-8693-884c48c42c20,\n            safariWebId: web.onesignal.auto.32d8157c-f1d5-44ab-a783-bc048d3cd7fd,\n          };\n        } else if (window.location.hostname.startsWith(cand.insights)) {\n          oneSignalIds  {\n            appId: 8737ec08-7bf4-4e82-87f0-220cc08a3c2a,\n            safariWebId: web.onesignal.auto.3a869b75-1942-4792-8237-9de8041a4c17,\n          };\n        } else if (window.location.hostname  www.chemistanddruggist.co.uk) {\n          oneSignalIds  {\n            appId: 20553d76-c568-47b5-8745-061464f5a6d3,\n            safariWebId: web.onesignal.auto.1b5e3a9a-fd8d-4cbc-b150-cc0a98b0f0fe,\n          };\n        } else if (window.location.hostname  www.chemistanddruggist.com) {\n          oneSignalIds  {\n            appId: 6d9b4011-5a92-4bb4-a8d2-01c75b10d65b,\n            safariWebId: web.onesignal.auto.3bb557bb-091e-4595-bac2-e40949e4ba5a,\n          };\n        } else if (window.location.hostname  web.insights.norstella-labs.com) {\n          oneSignalIds  {\n            appId: 22c36080-5e3f-4130-aa3d-f930814ff296,\n            safariWebId: web.onesignal.auto.26f438e4-4907-4b0f-9fba-4ab15d3b5c3b,\n          };\n        } else if (window.location.hostname  insights.citeline.com) {\n          oneSignalIds  {\n            appId: 9edc98e4-0160-4290-81db-bc46d50784ca,\n            safariWebId: web.onesignal.auto.44e66786-7e94-4ade-8822-3a1650cda83f,\n          };\n        } \n        else {\n          oneSignalIds  {\n            appId: 22c36080-5e3f-4130-aa3d-f930814ff296,\n            safariWebId: web.onesignal.auto.26f438e4-4907-4b0f-9fba-4ab15d3b5c3b,\n          };\n        } \n\n          window.OneSignalDeferred  window.OneSignalDeferred || ;\n          OneSignalDeferred.push(async function(OneSignal) {\n            await OneSignal.init({\n              appId: oneSignalIds.appId,\n              safari_web_id: oneSignalIds.safariWebId,\n              // allowLocalhostAsSecureOrigin: true,\n              notifyButton: {\n                enable: true,\n                size: medium,\n                position: bottom-right,\n                showCredit: false,\n                text: {\n                  tip.state.unsubscribed: Subscribe to notifications,\n                  tip.state.subscribed: \Youre subscribed to notifications\,\n                  tip.state.blocked: \Youve blocked notifications\,\n                  message.prenotify: Click to subscribe to notifications,\n                  message.action.subscribed: \Thanks for subscribing!\,\n                  message.action.resubscribed: \Youre subscribed to notifications\,\n                  message.action.unsubscribed: \You wont receive notifications again\,\n                  dialog.main.title: Manage Site Notifications,\n                  dialog.main.button.subscribe: SUBSCRIBE,\n                  dialog.main.button.unsubscribe: UNSUBSCRIBE,\n                  dialog.blocked.title: Unblock Notifications,\n                  dialog.blocked.message: \Follow these instructions to allow notifications:\\n                }\n              },\n              promptOptions: {\n                slidedown: {\n                  prompts: \n                    {\n                      type: \push\,\n                      autoPrompt: true,\n                      text: {\n                        actionMessage: \Wed like to show you notifications for the latest news and updates. You can disable anytime.\,\n                        acceptButton: \Allow\,\n                        cancelButton: \No Thanks\\n                      },\n                      delay: {\n                        pageViews: 2,\n                        timeDelay: 30\n                      }\n                    }\n                  \n                },\n                customlink: {\n                  enabled: true,\n                  style: \button\,\n                  size: \medium\,\n                  color: {\n                    button: #E12D30,\n                    text: #FFFFFF,\n                  },\n                  text: {\n                    subscribe: \Get Notifications\,\n                    unsubscribe: \Unsubscribe from notifications\,\n                    explanation: \Subscribe to our notifications for the latest news and updates. You can disable anytime.\,\n                  },\n                  unsubscribeEnabled: true,\n                }\n              },\n              promptOptions: {\n                slidedown: {\n                  prompts: \n                    {\n                      type: \push\,  // Push notification prompt\n                      autoPrompt: true, // Show automatically\n                      text: {\n                        actionMessage: \Subscribe to our notifications for the latest news and updates. You can disable anytime.\,\n                        acceptButton: \Subscribe\,\n                        cancelButton: \Later\\n                      },\n                      delay: {\n                        pageViews: 1, // Show after 1 page view\n                        timeDelay: 5  // Show after 5 seconds\n                      }\n                    }\n                  \n                }\n              },\n              showCredit: false, /* Hide the OneSignal logo */\n              text: {\n                  tip.state.unsubscribed: tip.state.unsubscribed,\n                  tip.state.subscribed: tip.state.subscribed,\n                  tip.state.blocked: tip.state.blocked,\n                  message.prenotify: message.prenotify,\n                  message.action.subscribed: message.action.subscribed,\n                  message.action.resubscribed: message.action.resubscribed,\n                  message.action.unsubscribed: message.action.unsubscribed,\n                  dialog.main.title: dialog.main.title,\n                  dialog.main.button.subscribe: dialog.main.button.subscribe,\n                  dialog.main.button.unsubscribe: dialog.main.button.unsubscribe,\n                  dialog.blocked.title: dialog.blocked.title,\n                  dialog.blocked.message: dialog.blocked.message\n              }\n            });\n          });\n          ,\n    (function() {\n      // Execute immediately since this script runs after DOMContentLoaded\n      if (document.readyState  loading) {\n        document.addEventListener(DOMContentLoaded, function() {\n          queryly.init(\cc46eb7864d14022\, document.querySelectorAll(\#fusion-app\));\n        });\n      } else {\n        // DOM is already ready, initialize immediately\n        queryly.init(\cc46eb7864d14022\, document.querySelectorAll(\#fusion-app\));\n      }\n    })();\n  ;                  var runScript  function(scriptContent) {                    try {                      var script  document.createElement(script);                      script.type  text/javascript;                      script.text  scriptContent;                      document.body.appendChild(script);                    } catch(e) { console.error(Error executing deferred script, e); }                  };                  var schedule  window.requestIdleCallback || function(cb) { setTimeout(cb, 1); };                  var executeNext  function() {                    if (scripts.length  0) return;                    var nextScript  scripts.shift();                    runScript(nextScript);                    schedule(executeNext);                  };                                    if (window.addEventListener) {                    window.addEventListener(load, function() { schedule(executeNext); });                  } else {                    var oldOnLoad  window.onload;                    window.onload  function(e) {                      if (typeof oldOnLoad  function) oldOnLoad(e);                      schedule(executeNext);                    }                  }                })();              /script>script data-integrationonesignal-bootstrap>window.OneSignalDeferred  window.OneSignalDeferred || ;/script>script srchttps://cdn.onesignal.com/sdks/web/v16/OneSignalSDK.page.js>/script>script async data-integrationnativo-ad srchttps://s.ntv.io/serve/load.js>/script>script async data-integrationchartbeat srchttps://static.chartbeat.com/js/chartbeat.js>/script>script srchttps://cdn.cookielaw.org/scripttemplates/otSDKStub.js typetext/javascript charSetUTF-8 data-domain-script0191d6fd-7ef8-70e9-b518-3a716603333e-test async>/script>script>function OptanonWrapper() {}/script>script async srchttps://cdn-clavis-norstella-sandbox.arc-perso.aws.arc.pub/clavis.main.js.gz>/script>script>window.insightsSearchConfig  { companyApiUrl: https://tst.bmt-companies.citeline-labs.com, clientId: VWL5i1Egxi6dXH4Og8XD5mtGx1aZOydk, arcSite: insights };/script>script defer data-integrationqueryly srchttps://www.queryly.com/js/queryly.v4.min.js>/script>script>(window.BOOMR_mqwindow.BOOMR_mq||).push(addVar,{rua.upush:false,rua.cpush:false,rua.upre:false,rua.cpre:false,rua.uprl:false,rua.cprl:false,rua.cprf:false,rua.trans:,rua.cook:false,rua.ims:false,rua.ufprl:false,rua.cfprl:false,rua.isuxp:false,rua.texp:norulematch,rua.ceh:false,rua.ueh:false,rua.ieh.st:0});/script>                              script>!function(e){var nhttps://s.go-mpulse.net/boomerang/;if(FalseTrue)e.BOOMR_confige.BOOMR_config||{},e.BOOMR_config.PageParamse.BOOMR_config.PageParams||{},e.BOOMR_config.PageParams.pci!0,nhttps://s2.go-mpulse.net/boomerang/;if(window.BOOMR_API_key4EXQY-TU64N-3RXP6-W9FYA-M7P86,function(){function e(){if(!o){var edocument.createElement(script);e.idboomr-scr-as,e.srcwindow.BOOMR.url,e.async!0,i.parentNode.appendChild(e),o!0}}function t(e){o!0;var n,t,a,r,ddocument,Owindow;if(window.BOOMR.snippetMethode?if:i,tfunction(e,n){var td.createElement(script);t.idn||boomr-if-as,t.srcwindow.BOOMR.url,BOOMR_lstart(new Date).getTime(),ee||d.body,e.appendChild(t)},!window.addEventListener&&window.attachEvent&&navigator.userAgent.match(/MSIE 67\./))return window.BOOMR.snippetMethods,void t(i.parentNode,boomr-async);adocument.createElement(IFRAME),a.srcabout:blank,a.title,a.rolepresentation,a.loadingeager,r(a.frameElement||a).style,r.width0,r.height0,r.border0,r.displaynone,i.parentNode.appendChild(a);try{Oa.contentWindow,dO.document.open()}catch(_){ndocument.domain,a.srcjavascript:var ddocument.open();d.domain+n+;void(0);,Oa.contentWindow,dO.document.open()}if(n)d._boomrlfunction(){this.domainn,t()},d.write(bo+dy onloaddocument._boomrl();>);else if(O._boomrlfunction(){t()},O.addEventListener)O.addEventListener(load,O._boomrl,!1);else if(O.attachEvent)O.attachEvent(onload,O._boomrl);d.close()}function a(e){window.BOOMR_onloade&&e.timeStamp||(new Date).getTime()}if(!window.BOOMR||!window.BOOMR.version&&!window.BOOMR.snippetExecuted){window.BOOMRwindow.BOOMR||{},window.BOOMR.snippetStart(new Date).getTime(),window.BOOMR.snippetExecuted!0,window.BOOMR.snippetVersion12,window.BOOMR.urln+4EXQY-TU64N-3RXP6-W9FYA-M7P86;var idocument.currentScript||document.getElementsByTagName(script)0,o!1,rdocument.createElement(link);if(r.relList&&functiontypeof r.relList.supports&&r.relList.supports(preload)&&asin r)window.BOOMR.snippetMethodp,r.hrefwindow.BOOMR.url,r.relpreload,r.asscript,r.addEventListener(load,e),r.addEventListener(error,function(){t(!0)}),setTimeout(function(){if(!o)t(!0)},3e3),BOOMR_lstart(new Date).getTime(),i.parentNode.appendChild(r);else t(!1);if(window.addEventListener)window.addEventListener(load,a,!1);else if(window.attachEvent)window.attachEvent(onload,a)}}(),.length>0)if(e&&performancein e&&e.performance&&functiontypeof e.performance.setResourceTimingBufferSize)e.performance.setResourceTimingBufferSize();!function(){if(BOOMRe.BOOMR||{},BOOMR.pluginsBOOMR.plugins||{},!BOOMR.plugins.AK){var ntrue?1:0,t,agquou2ixf3sdc2ll2t6q-f-a28168f73-clientnsv4-s.akamaihd.net,ifalsetrue?2:1,o{ak.v:39,ak.cp:1573342,ak.ai:parseInt(1008302,10),ak.ol:0,ak.cr:7,ak.ipv:4,ak.proto:http/1.1,ak.rid:8bd95d95,ak.r:50941,ak.a2:n,ak.m:,ak.n:ff,ak.bpcip:52.40.234.0,ak.cport:50787,ak.gh:23.32.14.17,ak.quicv:,ak.tlsv:tls1.2,ak.0rtt:,ak.0rtt.ed:,ak.csrc:-,ak.acc:bbr,ak.t:1768674557,ak.ak:hOBiQwZUYzCg5VSAfCLimQFND5pdUsHcwFbwwyoRoOYk5Frz8hyghssEHbEUZGMCqzC5KFlL+/2CEZ5FiwXOd7vYDR4MCItD+g3BYMTTZ6XlYOUeaymutBDyAbSHCyf0QoFGdvsWRWKyJGMi5PELdG4mXAlh+WVxnYIe32s8YV1BZEbAsy2GhKLh8ko3xeBfrgo+EXHUJ2zpVwqWLjC53eHgZQMIJ8+7+NA/IpGUbT4FzTzWBmS15414cwoXkCABTgowmRgyJxs+Fs9eqjJKo5zavTpjvxjNM3viveiaucQ0asxZHt3FIyOgGRmJ/3UAUr5eifZsMomFyrvh/xwEBw3xFuB7nlylwIWrZmCQ/5dyIvRwIXLUdQFxEdBc+cZa5ZasG3eGp4ifNN4MGQoeIDUM1Sz1fse0fiGhqn3Gk9qRdAubyIPcrjY9zSFwBCz14,ak.pv:10,ak.dpoabenc:,ak.tf:i};if(!t)oak.rudst;var r{i:!1,av:function(n){var thttp.initiator;if(n&&(!nt||spa_hardnt))oak.feovoid 0!e.aFeoApplied?1:0,BOOMR.addVar(o)},rv:function(){var eak.bpcip,ak.cport,ak.cr,ak.csrc,ak.gh,ak.ipv,ak.m,ak.n,ak.ol,ak.proto,ak.quicv,ak.tlsv,ak.0rtt,ak.0rtt.ed,ak.r,ak.acc,ak.t,ak.tf;BOOMR.removeVar(e)}};BOOMR.plugins.AK{akVars:o,akDNSPreFetchDomain:a,init:function(){if(!r.i){var eBOOMR.subscribe;e(before_beacon,r.av,null,null),e(onbeacon,r.rv,null,null),r.i!0}return this},is_complete:function(){return!0}}}}()}(window);/script>/head>body>div idfusion-app classc-stack b-application data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>div classToastify>/div>div classb-right-rail>header classc-stack b-right-rail__navigation data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>nav idmain-nav classb-header-nav-chain  aria-labelSections Menu>div classb-header-nav-chain__top-layout>div classb-header-nav-chain__nav-left>div classnav-components--mobile>button classmenu-icon menu-icon- aria-labelmenu-icon>/button>/div>div classnav-components--desktop>button classmenu-icon menu-icon- aria-labelmenu-icon>/button>/div>/div>a titleLight logo alt text classc-link b-header-nav-chain__logo 'nav-logo-show'    href/>div class>img srchttps://static.themebuilder.aws.arc.pub/norstella/1715074117520.png altLight logo alt text data-chromaticignore/>/div>/a>nav aria-labelTop Links classc-stack b-header-nav-chain__links-list data-style-directionhorizontal data-style-justificationstart data-style-alignmentcenter data-style-inlinefalse data-style-wrapwrap>span classb-header-nav-chain__links-list-item>a classc-link href/pink-sheet>Pink Sheet/a>/span>span classb-header-nav-chain__links-list-item>a classc-link href/scrip>Scrip/a>/span>span classb-header-nav-chain__links-list-item>a classc-link href/medtech-insight>Medtech Insight/a>/span>span classb-header-nav-chain__links-list-item>a classc-link href/hbw-insight>HBW Insight/a>/span>span classb-header-nav-chain__links-list-item>a classc-link href/generics-bulletin>Generics Bulletin/a>/span>span classb-header-nav-chain__links-list-item>a classc-link href/in-vivo>In Vivo/a>/span>/nav>div classb-header-nav-chain__nav-right>div classnav-components--mobile>div classheader-buttons-wrap>div rolebutton tabindex0 aria-labelSearch classtop-search-button>div classtop-search-icon>/div>/div>div classhelp-dropdown-wrap>div rolebutton tabindex0 aria-haspopuptrue aria-expandedfalse aria-labelHelp menu>div classhelp-icon>/div>/div>/div>button classc-button c-button--medium c-button--primary mobile-button button-states typebutton>div classlogin-icon>/div>span>Sign In/span>/button>a target_blank classc-button c-button--link c-button--medium c-button--primary free-trial mobile-button hrefhttps://www.citeline.com/en/app-insights-trial>div classperson-add-icon>/div>span>Free Trial/span>/a>/div>/div>div classnav-components--desktop>div classheader-buttons-wrap>div rolebutton tabindex0 aria-labelSearch classtop-search-button>div classtop-search-icon>/div>/div>div classhelp-dropdown-wrap>div rolebutton tabindex0 aria-haspopuptrue aria-expandedfalse aria-labelHelp menu>div classhelp-icon>/div>/div>/div>button classc-button c-button--medium c-button--primary mobile-button button-states typebutton>div classlogin-icon>/div>span>Sign In/span>/button>a target_blank classc-button c-button--link c-button--medium c-button--primary free-trial mobile-button hrefhttps://www.citeline.com/en/app-insights-trial>div classperson-add-icon>/div>span>Free Trial/span>/a>/div>/div>/div>/div>div idflyout-overlay data-testidnav-chain-flyout-overlay classc-stack b-header-nav-chain__flyout-overlay closed data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>div>div classc-stack b-header-nav-chain__flyout-nav-wrapper closed data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>div classnav-menu>div classc-stack nav-components--mobile data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>/div>div classc-stack nav-components--desktop data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>/div>/div>hr classc-divider/>div classc-stack b-header-nav-chain__flyout-nav nav-wrapper data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>div classsection-item>div classsection-anchor-wrapper  >a classc-link href/in-vivo>In Vivo/a>/div>/div>hr aria-hiddentrue/>div classsection-item>div classsection-anchor-wrapper  >a classc-link href/generics-bulletin>Generics Bulletin/a>/div>/div>hr aria-hiddentrue/>div classsection-item>div classsection-anchor-wrapper  >a classc-link href/hbw-insight>HBW Insight/a>/div>/div>hr aria-hiddentrue/>div classsection-item>div classsection-anchor-wrapper  >a classc-link href/medtech-insight>Medtech Insight/a>/div>/div>hr aria-hiddentrue/>div classsection-item>div classsection-anchor-wrapper  >a classc-link href/pink-sheet>Pink Sheet/a>/div>/div>hr aria-hiddentrue/>div classsection-item>div classsection-anchor-wrapper  >a classc-link href/scrip>Scrip/a>/div>/div>/div>/div>/div>/div>/nav>/header>section rolemain tabindex-1 classb-right-rail__main>div classc-stack b-right-rail__full-width-1  data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>div idfusion-static-enter:html-block-f0fIW5bNfAVN1x6 styledisplay:none data-fusion-componenthtml-block-f0fIW5bNfAVN1x6>/div>div>style>h1.tagline {overflow: hidden;position: absolute;height: 1px;}/style>h1 classtagline>Citeline, a Norstella company/h1>/div>div idfusion-static-exit:html-block-f0fIW5bNfAVN1x6 styledisplay:none data-fusion-componenthtml-block-f0fIW5bNfAVN1x6>/div>div idfusion-static-enter:html-block-f0fRDvrga1eA1xc styledisplay:none data-fusion-componenthtml-block-f0fRDvrga1eA1xc>/div>div classb-html-box__content stylefont-family:Lexend, Arial, sans-serif;margin-block-end:1.5rem>div idheroContainer classhpsection>div classheader-with-divider>h2 classc-heading>News. Context. span>Impact./span>/h2>/div>p>In-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries./p>a classc-button c-button--link c-button--medium c-button--primary highlight_button button-states href/search/?query*>span>Search Our Website/span>/a>/div>/div>div idfusion-static-exit:html-block-f0fRDvrga1eA1xc styledisplay:none data-fusion-componenthtml-block-f0fRDvrga1eA1xc>/div>div classc-stack b-single-chain data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>div classc-stack b-single-chain__children-stack data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>div idfusion-static-enter:html-block-f0f3gr8zoIru2C styledisplay:none data-fusion-componenthtml-block-f0f3gr8zoIru2C>/div>div>div idmostRead classhpsection>h2>Recent Articles/h2>/div>/div>div idfusion-static-exit:html-block-f0f3gr8zoIru2C styledisplay:none data-fusion-componenthtml-block-f0f3gr8zoIru2C>/div>div classread-more-wrapper read-more-wrapper_four>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/generics-bulletin/test-article-XL7YDJHZZNH4DOBDZRXW44KSOM/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://static.themebuilder.aws.arc.pub/norstella/1715074117695.png altTest article loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/generics-bulletin/test-article-XL7YDJHZZNH4DOBDZRXW44KSOM/>Test article/a>/h2>/div>div classrow>time astime classc-date row_item dateTime2026-01-13T13:07:45.991Z>Jan 13 2026/time>/div>p classc-paragraph>Thermo Fisher Scientific was one of the first companies in its peer group to have its near and long-term net-zero targets validated by the Science Based Targets initiative (SBTi)./p>/div>/div>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/PS154848/COVID-Vaccines-US-FDA-Changes-Course-Wants-New-Formulas-To-Target-KP2-Subvariant-If-Feasible/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://static.themebuilder.aws.arc.pub/norstella/1715074117695.png altCOVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’ loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/PS154848/COVID-Vaccines-US-FDA-Changes-Course-Wants-New-Formulas-To-Target-KP2-Subvariant-If-Feasible/>COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’/a>/h2>/div>div classrow>time astime classc-date row_item dateTime2026-01-05T09:28:26.952Z>Jan 05 2026/time>/div>p classc-paragraph>Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’/p>/div>/div>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/generics-bulletin/business/covid-searches-KN4S6IU65JF35EZHKXV232KAOM/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://static.themebuilder.aws.arc.pub/norstella/1715074117695.png altCovid searches loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/generics-bulletin/business/covid-searches-KN4S6IU65JF35EZHKXV232KAOM/>Covid searches/a>/h2>/div>div classrow>time astime classc-date row_item dateTime2026-01-05T08:56:03.729Z>Jan 05 2026/time>/div>p classc-paragraph>/p>/div>/div>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/pink-sheet/podcasts/nancy-tests-new-podcast-template-UEZLL73UQNDRNEUGKSTMSAFZPY/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://web.insights.norstella-labs.com/resizer/v2/RYW7642ZYRLN7P6PWMG5PI7I7Q.png?authfd8c4368d739d59f5ebf880cbca5ca7cad7160a9e5caefd0a68447b742126456&width400 altNancy Tests New Podcast Template loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/pink-sheet/podcasts/nancy-tests-new-podcast-template-UEZLL73UQNDRNEUGKSTMSAFZPY/>Nancy Tests New Podcast Template/a>/h2>/div>div classrow>time astime classc-date row_item dateTime2025-12-16T13:38:29.713Z>Dec 16 2025/time>/div>p classc-paragraph>Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions./p>/div>/div>div classc-stack read-more-wrapper_button_four data-style-directionvertical data-style-justificationstart data-style-alignmentend data-style-inlinefalse data-style-wrapnowrap>button aria-labelSee more stories classc-button c-button--medium c-button--primary button-states typebutton>span classvisually-hidden>See more stories/span>span>See More/span>/button>/div>/div>/div>/div>div idfusion-static-enter:html-block-f0fGH15u1FsC66J styledisplay:none data-fusion-componenthtml-block-f0fGH15u1FsC66J>/div>div>div idmostRead classhpsection>h2>Most Read Articles - TEST two 4x1 CONFIG/h2>/div>/div>div idfusion-static-exit:html-block-f0fGH15u1FsC66J styledisplay:none data-fusion-componenthtml-block-f0fGH15u1FsC66J>/div>div classc-stack b-single-chain data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>div classc-stack b-single-chain__children-stack  style--b-single-chain-children-stack-gap:1.5rem data-style-directionvertical>div classread-more-wrapper read-more-wrapper_four>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/PS154848/COVID-Vaccines-US-FDA-Changes-Course-Wants-New-Formulas-To-Target-KP2-Subvariant-If-Feasible/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://static.themebuilder.aws.arc.pub/norstella/1715074117695.png altCOVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’ loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/PS154848/COVID-Vaccines-US-FDA-Changes-Course-Wants-New-Formulas-To-Target-KP2-Subvariant-If-Feasible/>COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’/a>/h2>/div>div classrow>time astime classc-date row_item dateTime2026-01-05T09:28:26.952Z>Jan 05 2026/time>/div>p classc-paragraph>Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’/p>/div>/div>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/pink-sheet/podcasts/nancy-tests-new-podcast-template-UEZLL73UQNDRNEUGKSTMSAFZPY/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://web.insights.norstella-labs.com/resizer/v2/RYW7642ZYRLN7P6PWMG5PI7I7Q.png?authfd8c4368d739d59f5ebf880cbca5ca7cad7160a9e5caefd0a68447b742126456&width400 altNancy Tests New Podcast Template loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/pink-sheet/podcasts/nancy-tests-new-podcast-template-UEZLL73UQNDRNEUGKSTMSAFZPY/>Nancy Tests New Podcast Template/a>/h2>/div>div classrow>time astime classc-date row_item dateTime2025-12-16T13:38:29.713Z>Dec 16 2025/time>/div>p classc-paragraph>Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions./p>/div>/div>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/pink-sheet/podcasts/pink-sheet-podcast-understanding-the-us-fdas-cder-leadership-shuffle-QARSICCAUJEU3KLTHHDWFNIO6M/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://web.insights.norstella-labs.com/resizer/v2/Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q.png?auth83067321da81600860bdc1fc05b6d23dd01fb08e648d4706d36780a0a8f5f377&width400 altPink Sheet Podcast: Understanding the US FDA’s CDER Leadership Shuffle  loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/pink-sheet/podcasts/pink-sheet-podcast-understanding-the-us-fdas-cder-leadership-shuffle-QARSICCAUJEU3KLTHHDWFNIO6M/>Pink Sheet Podcast: Understanding the US FDA’s CDER Leadership Shuffle /a>/h2>/div>div classrow>time astime classc-date row_item dateTime2025-12-10T03:26:54.241Z>Dec 10 2025/time>/div>p classc-paragraph>Pink Sheet reporter and editors discuss the likely impacts of Center for Drug Evaluation and Research Director Richard Pazdur’s retirement from the FDA and Tracy Beth Høeg becoming the center’s acting director./p>/div>/div>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ADRPK3O2VJET7LRMHH367XHTFE/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://web.insights.norstella-labs.com/resizer/v2/Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q.png?auth83067321da81600860bdc1fc05b6d23dd01fb08e648d4706d36780a0a8f5f377&width400 altQuick Listen: Scrip’s Five Must-Know Things loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ADRPK3O2VJET7LRMHH367XHTFE/>Quick Listen: Scrip’s Five Must-Know Things/a>/h2>/div>div classrow>time astime classc-date row_item dateTime2025-12-09T18:58:33.274Z>Dec 09 2025/time>/div>p classc-paragraph>In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab. /p>/div>/div>/div>/div>/div>div classc-stack b-single-chain data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>div classc-stack b-single-chain__children-stack  style--b-single-chain-children-stack-gap:1.5rem data-style-directionvertical>div classread-more-wrapper read-more-wrapper_four>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/generics-bulletin/test-article-XL7YDJHZZNH4DOBDZRXW44KSOM/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://static.themebuilder.aws.arc.pub/norstella/1715074117695.png altTest article loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/generics-bulletin/test-article-XL7YDJHZZNH4DOBDZRXW44KSOM/>Test article/a>/h2>/div>div classrow>time astime classc-date row_item dateTime2026-01-13T13:07:45.991Z>Jan 13 2026/time>/div>p classc-paragraph>Thermo Fisher Scientific was one of the first companies in its peer group to have its near and long-term net-zero targets validated by the Science Based Targets initiative (SBTi)./p>/div>/div>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/generics-bulletin/business/covid-searches-KN4S6IU65JF35EZHKXV232KAOM/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://static.themebuilder.aws.arc.pub/norstella/1715074117695.png altCovid searches loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/generics-bulletin/business/covid-searches-KN4S6IU65JF35EZHKXV232KAOM/>Covid searches/a>/h2>/div>div classrow>time astime classc-date row_item dateTime2026-01-05T08:56:03.729Z>Jan 05 2026/time>/div>p classc-paragraph>/p>/div>/div>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/generics-bulletin/podcasts/podcast-subtype-sample-vigya-ZMOJPDF67BGDTGPHDP5T222TXE/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://web.insights.norstella-labs.com/resizer/v2/Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q.png?auth83067321da81600860bdc1fc05b6d23dd01fb08e648d4706d36780a0a8f5f377&width400 altPodcast subtype sample-vigya loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/generics-bulletin/podcasts/podcast-subtype-sample-vigya-ZMOJPDF67BGDTGPHDP5T222TXE/>Podcast subtype sample-vigya/a>/h2>/div>div classrow>time astime classc-date row_item dateTime2025-12-16T09:31:23.662Z>Dec 16 2025/time>/div>p classc-paragraph>In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab. /p>/div>/div>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/generics-bulletin/archive/embracing-chinas-brave-new-pharmaceutical-world-clone-clone-DRC2QVH7MZFV3JJFX7QIDAVAOQ/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://static.themebuilder.aws.arc.pub/norstella/1715074117695.png altEmbracing China’s Brave New Pharmaceutical World! - Clone - Clone! loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/generics-bulletin/archive/embracing-chinas-brave-new-pharmaceutical-world-clone-clone-DRC2QVH7MZFV3JJFX7QIDAVAOQ/>Embracing China’s Brave New Pharmaceutical World! - Clone - Clone!/a>/h2>/div>div classrow>time astime classc-date row_item dateTime2025-12-09T10:45:53.703Z>Dec 09 2025/time>/div>p classc-paragraph>Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change. /p>/div>/div>/div>/div>/div>div idfusion-static-enter:html-block-f0fn3LRbvMj853H styledisplay:none data-fusion-componenthtml-block-f0fn3LRbvMj853H>/div>div>div idmostRead classhpsection>h2>Citeline Podcasts/h2>/div>/div>div idfusion-static-exit:html-block-f0fn3LRbvMj853H styledisplay:none data-fusion-componenthtml-block-f0fn3LRbvMj853H>/div>div classc-stack b-single-chain data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>div classc-stack b-single-chain__children-stack  style--b-single-chain-children-stack-gap:1.5rem data-style-directionvertical>div classread-more-wrapper read-more-wrapper_four>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/pink-sheet/podcasts/nancy-tests-new-podcast-template-UEZLL73UQNDRNEUGKSTMSAFZPY/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://web.insights.norstella-labs.com/resizer/v2/RYW7642ZYRLN7P6PWMG5PI7I7Q.png?authfd8c4368d739d59f5ebf880cbca5ca7cad7160a9e5caefd0a68447b742126456&width400 altNancy Tests New Podcast Template loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/pink-sheet/podcasts/nancy-tests-new-podcast-template-UEZLL73UQNDRNEUGKSTMSAFZPY/>Nancy Tests New Podcast Template/a>/h2>/div>div classrow>time astime classc-date row_item dateTime2025-12-16T13:38:29.713Z>Dec 16 2025/time>/div>p classc-paragraph>Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions./p>/div>/div>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/generics-bulletin/podcasts/podcast-subtype-sample-vigya-ZMOJPDF67BGDTGPHDP5T222TXE/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://web.insights.norstella-labs.com/resizer/v2/Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q.png?auth83067321da81600860bdc1fc05b6d23dd01fb08e648d4706d36780a0a8f5f377&width400 altPodcast subtype sample-vigya loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/generics-bulletin/podcasts/podcast-subtype-sample-vigya-ZMOJPDF67BGDTGPHDP5T222TXE/>Podcast subtype sample-vigya/a>/h2>/div>div classrow>time astime classc-date row_item dateTime2025-12-16T09:31:23.662Z>Dec 16 2025/time>/div>p classc-paragraph>In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab. /p>/div>/div>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/pink-sheet/podcasts/pink-sheet-podcast-understanding-the-us-fdas-cder-leadership-shuffle-QARSICCAUJEU3KLTHHDWFNIO6M/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://web.insights.norstella-labs.com/resizer/v2/Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q.png?auth83067321da81600860bdc1fc05b6d23dd01fb08e648d4706d36780a0a8f5f377&width400 altPink Sheet Podcast: Understanding the US FDA’s CDER Leadership Shuffle  loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/pink-sheet/podcasts/pink-sheet-podcast-understanding-the-us-fdas-cder-leadership-shuffle-QARSICCAUJEU3KLTHHDWFNIO6M/>Pink Sheet Podcast: Understanding the US FDA’s CDER Leadership Shuffle /a>/h2>/div>div classrow>time astime classc-date row_item dateTime2025-12-10T03:26:54.241Z>Dec 10 2025/time>/div>p classc-paragraph>Pink Sheet reporter and editors discuss the likely impacts of Center for Drug Evaluation and Research Director Richard Pazdur’s retirement from the FDA and Tracy Beth Høeg becoming the center’s acting director./p>/div>/div>div>div classarticle-item article-item-border >div classarticle-item_image_wrapper>a href/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ADRPK3O2VJET7LRMHH367XHTFE/ aria-hiddentrue tabindex-1>img classarticle-item_image srchttps://web.insights.norstella-labs.com/resizer/v2/Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q.png?auth83067321da81600860bdc1fc05b6d23dd01fb08e648d4706d36780a0a8f5f377&width400 altQuick Listen: Scrip’s Five Must-Know Things loadinglazy/>/a>/div>div classarticle-item_title_wrapper>h2 classc-heading>a classc-link href/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ADRPK3O2VJET7LRMHH367XHTFE/>Quick Listen: Scrip’s Five Must-Know Things/a>/h2>/div>div classrow>time astime classc-date row_item dateTime2025-12-09T18:58:33.274Z>Dec 09 2025/time>/div>p classc-paragraph>In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab. /p>/div>/div>/div>/div>/div>div idfusion-static-enter:html-block-f0foupGIwuKZ16V styledisplay:none data-fusion-componenthtml-block-f0foupGIwuKZ16V>/div>div classb-html-box__content stylefont-family:Lexend, Arial, sans-serif;margin-block-end:1.5rem>div idquoteContainer classhpsection>div classslideshow-container>div classquote-block__quote-mark>/div>div classmySlides fade>  div classtext>strong>Scrip/strong>is an invaluable source of information and insight about key developments in the biopharmaceutical industry. It has produced some of the most detailed reporting about emerging therapeutics in our field (the liver disease nonalcoholic steatohepatitis), with crisp perspective on scientific, business and regulatory dynamics./div>p>strong>Chris Frates/strong>, VP of Corporate Communications and Patient Advocacybr>span>Madrigal Pharmaceuticals/span>/p>/div>div classmySlides fade>  div classtext>Ive been readingstrong>Generics Bulletin/strong> for over a decade now and it is really of great help to understand the latest news related to generics and biosimilars, including Licensing and M&A deals as well as new Authorities regulations./div>p>strong>Alex Falgas/strong>, Global SVP - BD Portfolio & Strategybr>span>Corporate Europe & MENA, Accord Healthcare/span>/p>/div>div classmySlides fade>  div classtext>strong>Medtech Insight/strong>is my go-to source for everything medical devices in the EU and UK. Medtech Insight not only provides timely updates but also analysis that provides insight beyond mere description/div>p>strong>Johan Ordish/strong>, Head of Digital Health and Innovation Policybr>span>Roche Diagnostics/span>/p>/div>/div>br>div styletext-align:center>  span classdot>/span>   span classdot>/span>   span classdot>/span> /div>/div>/div>div idfusion-static-exit:html-block-f0foupGIwuKZ16V styledisplay:none data-fusion-componenthtml-block-f0foupGIwuKZ16V>/div>div idfusion-static-enter:html-block-f0fIheIfGPhj1o0 styledisplay:none data-fusion-componenthtml-block-f0fIheIfGPhj1o0>/div>div classb-html-box__content stylefont-family:Lexend, Arial, sans-serif;margin-block-end:1.5rem>script>let slideIndex  0;showSlides();function showSlides() {  let i;  let slides  document.getElementsByClassName(mySlides);  let dots  document.getElementsByClassName(dot);  for (i  0; i  slides.length; i++) {    slidesi.style.display  none;    }  slideIndex++;  if (slideIndex > slides.length) {slideIndex  1}      for (i  0; i  dots.length; i++) {    dotsi.className  dotsi.className.replace( active, );  }  slidesslideIndex-1.style.display  block;    dotsslideIndex-1.className +  active;  setTimeout(showSlides, 7000); // Change image every 7 seconds}/script>/div>div idfusion-static-exit:html-block-f0fIheIfGPhj1o0 styledisplay:none data-fusion-componenthtml-block-f0fIheIfGPhj1o0>/div>div idfusion-static-enter:html-block-f0fgoJT0iyRJ2PM styledisplay:none data-fusion-componenthtml-block-f0fgoJT0iyRJ2PM>/div>div classb-html-box__content stylefont-family:Lexend, Arial, sans-serif;margin-block-end:1.5rem>div idourPubs classhpsection>h2>Our Publications/h2>p>A comprehensive and dependable information source aimed at ensuring industry leaders can stay on top of the latest regulatory, legal, market and commercial developments to anticipate potential threats and identify new opportunities./p>div classpubContainer>a classpubcards-link href/pink-sheet>div classcard>  img srchttps://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/H3276TUFFJMXLHNWTJMIOPLHOQ.jpg altPink Sheet loadinglazy width340 height204>  div classcardContainer>    h3>Regulatory & Policy/h3>    p>Essential updates and comprehensive coverage of industry regulations and emerging policy trends./p>  /div>/div>/a>a classpubcards-link href/scrip>div classcard>  img srchttps://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/PJWNZDT72JLOVP4VL2ZEFCUB64.jpg altScrip loadinglazy width340 height204>  div classcardContainer>    h3>Commercial Insights/h3>    p>In-depth analysis of the global biopharma industry, offering news that goes beyond the headlines./p>  /div>/div>/a>a classpubcards-link href/in-vivo>div classcard>  img srchttps://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/25NBFOMSIJKN3DR6PDRFZWDCVU.jpg altIn Vivo  loadinglazy width340 height204>  div classcardContainer>    h3>Executive Perspectives/h3>    p>Exclusive interviews, expert opinion, and critical insights tailored for life science decision-makers./p>  /div>/div>/a>a classpubcards-link href/medtech-insight>div classcard>  img srchttps://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/ZM6WHG6WIBIEXNMFJN7XUJAFSA.jpg altMedtech Insight loadinglazy width340 height204>  div classcardContainer>    h3>Medical Technology/h3>    p>Contextualized reporting on medtech advancements, market dynamics, industry data, and expert insights./p>  /div>/div>/a>a classpubcards-link href/generics-bulletin>div classcard>  img srchttps://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/5DMQHL7EKZNITECAZSZHMZOHL4.jpg altAvatar loadinglazy width340 height204>  div classcardContainer>    h3>Off-Patent Medicines/h3>    p>Unrivalled news and analysis of the global generic, biosimilars and value-added medicines industries./p>  /div>/div>/a>a classpubcards-link href/hbw-insight>div classcard>  img srchttps://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/5QRXNUACWJPKHB6LA2JAETGVSM.jpg altHBW Insight loadinglazy width340 height204>  div classcardContainer>    h3>Health & Wellness/h3>    p>Your primary source for impactful news and insights in the health, beauty, and wellness industries./p>  /div>/div>/a>/div>/div>/div>div idfusion-static-exit:html-block-f0fgoJT0iyRJ2PM styledisplay:none data-fusion-componenthtml-block-f0fgoJT0iyRJ2PM>/div>div idfusion-static-enter:html-block-f0f3iIbuGVZTMg styledisplay:none data-fusion-componenthtml-block-f0f3iIbuGVZTMg>/div>div classb-html-box__content stylefont-family:Lexend, Arial, sans-serif;margin-block-end:1.5rem>div iddepthAnalysis classhpsection>div classfifty-fifty__container >div classfifty-fifty__image-wrapper>img srchttps://www.citeline.com/-/media/citeline/product-services/commercialization/generic-bulletin/50-50.png classfifty-fifty__image altIn Depth Industry Analysis>/div>div classfifty-fifty__content>h2 styletext-align:left;>In-Depth Industry Analysis/h2>div classfifty-fifty__content-body rich-text-block>p>A comprehensive and dependable information source aimed at ensuring industry leaders can stay on top of the latest regulatory, legal, market and commercial developments to anticipate potential threats and identify new opportunities./p>p>Analysis and opinion covers key topic areas such as:/p>ul>    li>regulatory and compliance changes/li>    li>legal and legislations advances/li>    li>competitive developments/li>    li>merger and acquisition activities/li>    li>new product launches/li>/ul>			/div>		/div>	/div>/div>/div>div idfusion-static-exit:html-block-f0f3iIbuGVZTMg styledisplay:none data-fusion-componenthtml-block-f0f3iIbuGVZTMg>/div>div idfusion-static-enter:html-block-f0fJBQH3CmQ33Bn styledisplay:none data-fusion-componenthtml-block-f0fJBQH3CmQ33Bn>/div>div>div classfig_desc_container>div classfig_desc>p classfigure>400/p>p classfig_description>Articles/p>/div>div classfig_desc>p classfigure>50/p>p classfig_description>Podcasts/p>/div>div classfig_desc>p classfigure>100/p>p classfig_description>Analysis/p>/div>div classfig_desc>p classfigure>20/p>p classfig_description>Conference Coverage/p>/div>/div>/div>div idfusion-static-exit:html-block-f0fJBQH3CmQ33Bn styledisplay:none data-fusion-componenthtml-block-f0fJBQH3CmQ33Bn>/div>div idfusion-static-enter:html-block-f0fzD3RmPgfXGe styledisplay:none data-fusion-componenthtml-block-f0fzD3RmPgfXGe>/div>div classb-html-box__content stylefont-family:Lexend, Arial, sans-serif;margin-block-end:1.5rem>div idmobileApp classsection>div classcontainer>div>img srchttps://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/34LNQC5ISBCHPDTNVK2IETDJHY.png altCiteline app>/div>div>p>Sign up today andbr> see for yourself how we can help./p>a classc-button c-button--link c-button--medium c-button--primary highlight_button button-states hrefhttps://www.citeline.com/en/products-services/commercialization/citeline-news-and-insights-app target_blank>span>Download App/span>/a>/div>/div>/div>/div>/div>div idfusion-static-exit:html-block-f0fzD3RmPgfXGe styledisplay:none data-fusion-componenthtml-block-f0fzD3RmPgfXGe>/div>div idfusion-static-enter:html-block-f0fY6aB9ToFa12c styledisplay:none data-fusion-componenthtml-block-f0fY6aB9ToFa12c>/div>div classb-html-box__content stylefont-family:Lexend, Arial, sans-serif;margin-block-end:1.5rem>div idmeetTeam classhpsection>  h2>Meet The Team/h2>  br>  div classcontainer>    div>      img        srchttps://cloudfront-us-east-1.images.arcpublishing.com/norstella/3UCAMJEUPBCF3AU354OIP3PBSM.png        stylewidth:200px;height:200px;object-fit:cover;        width200 height200        altKaren Coleman loadinglazy>      p classname>Karen Coleman/p>      p classtitle>Executive Director,br> News and Insights/p>    /div>    div>      img        srchttps://cloudfront-us-east-1.images.arcpublishing.com/norstella/3ARRTK6C5ZEDZKNG3H4PPIDBFE.png        stylewidth:200px;height:200px;object-fit:cover;        width200 height200        altIan Haydock loadinglazy>      p classname>Ian Haydock/p>      p classtitle>Editor-in-Chief,br> APAC/p>    /div>    div>      img        srchttps://cloudfront-us-east-1.images.arcpublishing.com/norstella/DBHW25RDPJGBJFHC6ST3CB27VM.png        stylewidth:200px;height:200px;object-fit:cover;        width200 height200        altMatt Hobbs loadinglazy>      p classname>Nielsen Hobbs/p>      p classtitle>Interim Editor-in-Chief,br> em>Pink Sheet/em>/p>    /div>    div>      img        srchttps://cloudfront-us-east-1.images.arcpublishing.com/norstella/5BJDPWIWFZFZTPAUXNVRL25BPM.png        stylewidth:200px;height:200px;object-fit:cover;        width200 height200        altEleanor Malone loadinglazy>      p classname>Eleanor Malone/p>      p classtitle>Editor-in-Chief,br> Commercial Insights/p>    /div>    div>      img        srchttps://cloudfront-us-east-1.images.arcpublishing.com/norstella/BJSNON6BXFCXXB6PBNU5RHO4RA.png        stylewidth:200px;height:200px;object-fit:cover;        width200 height200        altRyan Nelson loadinglazy>      p classname>Ryan Nelson/p>      p classtitle>Editor-in-Chief,br> em>HBW Insight, Medtech Insight/em>/p>    /div>  /div>  br>br>  div styletext-align:center;>    a classc-button c-button--link c-button--medium c-button--primary highlight_button button-states href/meet-the-team>      span>Meet The Team/span>    /a>  /div>/div>/div>div idfusion-static-exit:html-block-f0fY6aB9ToFa12c styledisplay:none data-fusion-componenthtml-block-f0fY6aB9ToFa12c>/div>div idfusion-static-enter:html-block-f0fmv5QMmYGX1g6 styledisplay:none data-fusion-componenthtml-block-f0fmv5QMmYGX1g6>/div>div>div idquestionsSection classhpsection>h2>Questions?/h2>p>Reach out to a hrefmailto:#>emailaddress@emailaddress.com/p>/div>/div>div idfusion-static-exit:html-block-f0fmv5QMmYGX1g6 styledisplay:none data-fusion-componenthtml-block-f0fmv5QMmYGX1g6>/div>div idfusion-static-enter:html-block-f0f0M8iwa1eA1zw styledisplay:none data-fusion-componenthtml-block-f0f0M8iwa1eA1zw>/div>div classb-html-box__content stylefont-family:Lexend, Arial, sans-serif;margin-block-end:1.5rem>style>  .c-stack.b-right-rail__full-width-1  {  background: #f2f2f2;  overflow: hidden;  margin-top: -50px;  max-inline-size: none;  }  .c-stack.b-right-rail__full-width-1 .c-stack.b-single-chain {  margin: 0 auto;  overflow: hidden;  }.c-stack.b-right-rail__full-width-1 .c-stack.b-single-chain {}.full-width2-container {display: none;}.b-right-rail__footer {margin-top: -5rem;}/* Top Section */  #heroContainer {  font-family:lexend,arial,sans-serif;  margin-top: 2rem;  text-align: center;margin: -1rem -3rem;background-color: var(--global-navy);  }  #heroContainer .c-heading span {  background-color: #8700c3;  padding: .1rem .7rem;  border-radius: 3rem;  line-height: 1.7;color: white;  }  #heroContainer p {  margin: 1rem 0;  }#heroContainer h2 {font-size: 34px;}  .navy-heading {  color: var(--global-navy);  font-weight: bold !important;  }  .b-search-results-list {  width:730px;  }  .hpsection {  padding: 3rem;  font-family: lexend, poppins, arial, sans-serif;  color: white;  }  .hpsection h2 {  font-size: var(--global-font-size-9);  text-align: center;margin-bottom:1rem;  }  .header-with-divider {  text-align: center;  color: white;  }  .c-stack.b-single-chain:nth-child(2) {      background-color: white;      padding: 2rem;  }  div.section {  font-family: lexend, poppins,arial,sans-serif;  }/* Latest Content Section */#mostRead {padding: 0;color: var(--global-navy);}    /* Our Publications Section */  #ourPubs {  background-color: white;  text-align: center;padding: 3rem 6rem;    margin: 0 -1rem;    overflow: auto;background: url(https://www.citeline.com/dist/images/insights-events-bg.png) no-repeat fixed 50% / cover;  }#ourPubs h2 {color: white;}#ourPubs p {max-width: 1200px;margin: 0 auto;}    .pubContainer {  display: flex;  flex-wrap: wrap;  justify-content: center;margin: 2rem auto;max-width: 1200px;  }    a.pubcards-link {      color: navy;      text-decoration: none;     grid-auto-flow: column;   display: -ms-grid;    display: grid;   }    .card {    transition: 0.3s;  background-color: #f2f2f2;  width: 340px;  border-radius: .625rem;margin: 1.5rem .5rem;text-align: left;font-weight: 300;font-size: 18px;  }    .card:hover {    box-shadow: 0 8px 16px 0 rgba(0,0,0,0.2);  }    .cardContainer {    padding: 1rem 1.5rem;  }  .card img {    object-fit: cover;    height: 12.75rem;border-top-left-radius: .625rem;border-top-right-radius: .625rem;  }.card h3 {font-size: 20px;}      /* Quote Section */     #quoteContainer {  background-color: white;      margin: 0 -3rem -5rem -3rem;color: #000;  }  .quote-block__quote-mark {    font-size: 5.625rem;    line-height: 1;    position: relative;    top: -5rem;    left: -2rem;}.quote-block__quote-mark:before {    content: “;    display: block;    color: #8700c3;}.mySlides {display: none;}.mySlides p {margin-top: 22px;font-size:18px;}.mySlides p span {color: #8700c3;}.slideshow-container {padding: 3rem;margin: 0 auto;height: 250px;font-size: 1.5rem;display: flex;align-items: center;width:1200px;}.dot {  cursor: pointer;  height: 15px;  width: 15px;  margin: 0 2px;  background-color: #bbb;  border-radius: 50%;  display: inline-block;  transition: background-color 0.6s ease;}.active, .dot:hover {  background-color: #717171;}/* Fading animation */.fade {  animation-name: fade;  animation-duration: 1.5s;}@keyframes fade {  from {opacity: .4}   to {opacity: 1}}/* On smaller screens, decrease text size */@media only screen and (max-width: 300px) {  .text {font-size: 11px}}  /* In Depth Analysis Section */#depthAnalysis {background-color: var(--global-navy);margin: -3rem;}.fifty-fifty__container {    margin-left: auto;    margin-right: auto;    max-width: 69.5rem;    display: flex;    justify-content: center;    gap: 1.25rem;color: white;}.fifty-fifty__image-wrapper {    flex: 1 0 0;    width: 100%;    position: relative;}.fifty-fifty__image {    height: 100%;    width: 100%;    border-radius: .625rem;    -o-object-fit: cover;    object-fit: cover;    -o-object-position: center;    object-position: center;}.fifty-fifty__content {    flex: 1 0 0;    display: flex;    flex-direction: column;    justify-content: center;}.fifty-fifty__container  ul {padding-inline-start: 1rem;margin-top: 1rem;}.fifty-fifty__container  ul li{margin-bottom:0.5rem!important;}   .fifty-fifty__container p:not(.fifty-fifty__content-title) {font-weight:200!important;}/* Most Read */ @media (min-width: 76rem) {    .read-more-wrapper_four {width: 1200px;}}/* Stats */.fig_desc_container {display: flex;color: white;place-content: space-evenly;margin: 0 -1rem -3rem;padding: 2rem 0 3rem;background-color: #8800c4;flex-wrap: wrap;}.fig_desc {font-family: lexend,poppins,arial,sans-serif;line-height: 1.2;}.fig_desc .figure {font-size:60px;font-weight:600;}  /* Mobile App Section */    .text-and-image, #mobileApp {  background-color:white;  }  #mobileApp {  padding: 3rem 6rem;      margin: 0 -1rem;  }  #mobileApp img {  width: 250px;margin-right: 2rem;  }  #mobileApp p {  font-size: 30px;  margin-bottom: 2rem;  }#mobileApp .container { width:900px;display: flex;align-items: center;margin: 0 auto;}/* Meet Team Section */#meetTeam {background-color: var(--global-navy);margin: 0 -3rem;}#meetTeam .container {    display: flex;    align-items: center;    text-align: center;    gap: 2rem;place-content: center;flex-wrap: wrap;}/* Questions Section */#questionsSection {background: white;color: var(--global-navy);margin: -1rem -3rem;text-align: center;}#questionsSection h2 {color: var(--global-navy);}  /* Responsive */@media only screen and (max-width: 1200px) {  .pubContainer {padding:0;}.slideshow-container {width: auto;height: auto;}#mobileApp div {width: auto;}}    /style>/div>div idfusion-static-exit:html-block-f0f0M8iwa1eA1zw styledisplay:none data-fusion-componenthtml-block-f0f0M8iwa1eA1zw>/div>/div>div classc-grid b-right-rail__rail-container container-rail>div classc-stack b-right-rail__main-interior-item data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>/div>aside classc-stack b-right-rail__main-right-rail  data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>/aside>/div>div classfull-width2-container >div classc-stack b-right-rail__full-width-2 data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>/div>/div>/section>footer classc-stack b-right-rail__footer data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>div classc-stack b-footer data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>div classc-stack footer-main norstella data-style-directionhorizontal data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>div classc-stack footer-logo-wrapper data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>img altLight logo alt text classc-image b-footer__logo srchttps://static.themebuilder.aws.arc.pub/norstella/1715074117520.png height96/>div classb-footer__social-links-container>div classc-stack b-footer__social-links data-style-directionhorizontal data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>a classc-link hrefhttps://x.com/Citeline relnoreferrer target_blank>svg classc-icon width48 height48 xmlnshttp://www.w3.org/2000/svg viewBox0 0 512 512 fillcurrentColor aria-hiddentrue focusablefalse>path dM389.2 48h70.6L305.6 224.2 487 464H345L233.7 318.6 106.5 464H35.8L200.7 275.5 26.8 48H172.4L272.9 180.9 389.2 48zM364.4 421.8h39.1L151.1 88h-42L364.4 421.8z>/path>/svg>span classvisually-hidden>Twitter feed/span>/a>a classc-link hrefhttps://www.linkedin.com/company/citeline/  relnoreferrer target_blank>svg classc-icon width48 height48 xmlnshttp://www.w3.org/2000/svg viewBox0 0 512 512 fillcurrentColor aria-hiddentrue focusablefalse>path dM448 32H63.9C46.3 32 32 46.5 32 64.3v383.4C32 465.5 46.3 480 63.9 480H448c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM167.4 416H101V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S112.9 96 134.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z>/path>/svg>span classvisually-hidden>RSS feed/span>/a>a classc-link hrefhttps://insights.citeline.com/arc/outboundfeeds/rss/>svg classc-icon width48 height48 xmlnshttp://www.w3.org/2000/svg viewBox0 0 512 512 fillcurrentColor aria-hiddentrue focusablefalse>path dM128.081 415.959c0 35.369-28.672 64.041-64.041 64.041S0 451.328 0 415.959s28.672-64.041 64.041-64.041 64.04 28.673 64.04 64.041zm175.66 47.25c-8.354-154.6-132.185-278.587-286.95-286.95C7.656 175.765 0 183.105 0 192.253v48.069c0 8.415 6.49 15.472 14.887 16.018 111.832 7.284 201.473 96.702 208.772 208.772.547 8.397 7.604 14.887 16.018 14.887h48.069c9.149.001 16.489-7.655 15.995-16.79zm144.249.288C439.596 229.677 251.465 40.445 16.503 32.01 7.473 31.686 0 38.981 0 48.016v48.068c0 8.625 6.835 15.645 15.453 15.999 191.179 7.839 344.627 161.316 352.465 352.465.353 8.618 7.373 15.453 15.999 15.453h48.068c9.034-.001 16.329-7.474 16.005-16.504z>/path>/svg>span classvisually-hidden>RSS feed/span>/a>a classc-link b-footer__social-link hrefhttps://podcasts.apple.com/us/podcast/citeline-podcasts/id923189836 relnoreferrer target_blank>img src/pf/resources/images/icons/podcast.svg?d1572 altPodcast classb-footer__social-icon/>span classvisually-hidden>Podcast/span>/a>a classc-link b-footer__social-link hrefhttps://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67 relnoreferrer target_blank>img src/pf/resources/images/icons/spotify.svg?d1572 altSpotify classb-footer__social-icon/>span classvisually-hidden>Spotify/span>/a>/div>/div>/div>div classc-stack footer-nav-container data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap>div classc-grid b-footer__links>div classb-footer__links-group>h2 classc-heading>About/h2>ul classb-footer__links-group-list>li classb-footer__links-group-list-item >a classc-link hrefhttps://www.citeline.com/en/solutions/news-and-insights relnoreferrer target_blank>About Usspan classvisually-hidden>Opens in new window/span>/a>/li>li classb-footer__links-group-list-item >a classc-link href/meet-the-team/>Meet the Team/a>/li>li classb-footer__links-group-list-item >a classc-link hrefhttps://www.citeline.com/en/products-services/marketing/pharma-ignite relnoreferrer target_blank>Advertisespan classvisually-hidden>Opens in new window/span>/a>/li>li classb-footer__links-group-list-item >a classc-link href/contact-us/>Contact Us/a>/li>/ul>/div>hr classfooter-links-group-divider/>div classb-footer__links-group>h2 classc-heading>Account/h2>ul classb-footer__links-group-list>li classb-footer__links-group-list-item >a classc-link href/my-account/contact-information/>My Account/a>/li>li classb-footer__links-group-list-item >a classc-link href/my-view-page/>My View/a>/li>li classb-footer__links-group-list-item >a classc-link href/my-account/email-preferences/>Email Preferences/a>/li>li classb-footer__links-group-list-item >a classc-link hrefhttps://www.citeline.com/en/app-insights-trial relnoreferrer target_blank>Start Free Trialspan classvisually-hidden>Opens in new window/span>/a>/li>/ul>/div>hr classfooter-links-group-divider/>div classb-footer__links-group>h2 classc-heading>Publications/h2>ul classb-footer__links-group-list>li classb-footer__links-group-list-item >a classc-link href/pink-sheet>Pink Sheet/a>/li>li classb-footer__links-group-list-item >a classc-link href/scrip>Scrip/a>/li>li classb-footer__links-group-list-item >a classc-link href/medtech-insight>Medtech Insight/a>/li>li classb-footer__links-group-list-item >a classc-link href/hbw-insight>HBW Insight/a>/li>li classb-footer__links-group-list-item >a classc-link href/generics-bulletin>Generics Bulletin/a>/li>li classb-footer__links-group-list-item >a classc-link href/in-vivo>In Vivo/a>/li>/ul>/div>/div>/div>/div>div classc-stack footer-links-container norstella data-style-directionvertical data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapnowrap style--c-stack-gap:24px>div classc-stack data-style-directionhorizontal data-style-justificationstart data-style-alignmentunset data-style-inlinefalse data-style-wrapwrap style--c-stack-gap:16px>a classc-link footer-links-item norstella hrefhttps://www.citeline.com/en/terms-of-use relnoreferrer target_blank>Terms and Conditionsspan classvisually-hidden>Opens in new window/span>/a>hr classc-divider/>a classc-link footer-links-item norstella hrefhttps://www.norstella.com/privacy-center/ relnoreferrer target_blank>Privacy Policyspan classvisually-hidden>Opens in new window/span>/a>/div>p classc-paragraph copyright norstella>/p>/div>/div>/footer>/div>/div>script idfusion-metadata typeapplication/javascript>window.Fusionwindow.Fusion||{};Fusion.arcSiteinsights;Fusion.contextPath/pf;Fusion.mxId00000000;Fusion.deployment1572;Fusion.globalContent{};Fusion.globalContentConfig{};Fusion.lastModified1768674558077;Fusion.contentCache{signing-service:{{\id\:\https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/XWJL7WGEH5LPBNNARY6RRNCDX4.jpg\}:{data:{hash:6d565545e8b76302be7dad068f0e9bac69953c2bb606a70bcd8d488e06679f55,type:sha256,_id:fb169c728efdee10d88d1a5a7c08cb370b1c03d7a2f4e7cc3913bc4844295fa1},expires:1800161551251,lastModified:1768625550402},{\id\:\https://static.themebuilder.aws.arc.pub/norstella/1715074117695.png\}:{data:{hash:751ca127826767178e6bb347c272a5e3add904a529c7565f496e08ed8b217e52,type:sha256,_id:d08f3ba0437bf826939db0004b1357cfb140e0c7e50ce30e5eb85014e5afd726},expires:1800133455862,lastModified:1768597454928}},site-service-hierarchy:{{\feature\:\header-nav-chain\,\hierarchy\:\main_navigation\}:{data:{children:{_id:/in-vivo,children:{_id:/in-vivo/growth,children:{_id:/in-vivo/growth/vc-playbook,children:,name:VC Playbook,node_type:section,site:{}},name:Growth,node_type:section,site:{}},{_id:/in-vivo/innovation,children:,name:Innovation,node_type:section,site:{}},{_id:/in-vivo/leadership,children:{_id:/in-vivo/leadership/c-suite-speaks,children:,name:C-Suite Speaks,node_type:section,site:{}},{_id:/in-vivo/leadership/rising-leaders,children:,name:Rising Leaders,node_type:section,site:{}},name:Leadership,node_type:section,site:{}},{_id:/in-vivo/market-access,children:,name:Market Access,node_type:section,site:{}},{_id:/in-vivo/market-intelligence,children:,name:Market Intelligence,node_type:section,site:{}},{_id:/in-vivo/deal-making,children:,name:Deal-Making,node_type:section,site:{}},{_id:/in-vivo/global-vision,children:,name:Global Vision,node_type:section,site:{}},{_id:/in-vivo/manufacturing,children:,name:Manufacturing Focus,node_type:section,site:{}},{_id:/in-vivo/new-science,children:,name:New Science,node_type:section,site:{}},{_id:/in-vivo/business-strategy,children:,name:Business Strategy,node_type:section,site:{}},{_id:/in-vivo/esg,children:{_id:/in-vivo/esg/diversity-and-inclusion,children:,name:Diversity & Inclusion,node_type:section,site:{}},name:ESG,node_type:section,site:{}},{_id:/in-vivo/outlook,children:{_id:/in-vivo/outlook/scrip-100,children:,name:Scrip 100,node_type:section,site:{}},{_id:/in-vivo/outlook/medtech-100,children:,name:Medtech 100,node_type:section,site:{}},{_id:/in-vivo/outlook/generics-top-50,children:,name:Generics Top 50,node_type:section,site:{}},name:Outlook,node_type:section,site:{}},{_id:/in-vivo/podcasts,children:,name:Podcasts,node_type:section,site:{}},{_id:link-CX6NBWDEY5HWLFFB5JUVGLVHJY,children:,display_name:Partnered Content,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/partnered-content/},name:In Vivo,node_type:section,site:{}},{_id:/generics-bulletin,children:{_id:/generics-bulletin/business,children:{_id:/generics-bulletin/business/strategy,children:,name:Strategy,node_type:section,site:{}},{_id:/generics-bulletin/business/deals,children:,name:Deals,node_type:section,site:{}},{_id:/generics-bulletin/business/manufacturing,children:,name:Manufacturing,node_type:section,site:{}},{_id:/generics-bulletin/business/earnings,children:,name:Earnings,node_type:section,site:{}},name:Business,node_type:section,site:{}},{_id:/generics-bulletin/leadership,children:{_id:/generics-bulletin/leadership/interviews,children:,name:Interviews,node_type:section,site:{}},name:Leadership,node_type:section,site:{}},{_id:/generics-bulletin/policy-and-regulation,children:,name:Policy & Regulation,node_type:section,site:{}},{_id:/generics-bulletin/legalandip,children:,name:Legal & IP,node_type:section,site:{}},{_id:/generics-bulletin/products,children:{_id:/generics-bulletin/products/generics,children:,name:Generics,node_type:section,site:{}},{_id:/generics-bulletin/products/biosimilars,children:,name:Biosimilars,node_type:section,site:{}},{_id:/generics-bulletin/products/value-added-medicines,children:,name:Value Added Medicines,node_type:section,site:{}},name:Products,node_type:section,site:{}},{_id:/generics-bulletin/market-intelligence,children:{_id:/generics-bulletin/market-intelligence/company-rankings,children:,name:Company Rankings,node_type:section,site:{}},{_id:/generics-bulletin/market-intelligence/pricewatch-UK,children:,name:Pricewatch UK,node_type:section,site:{}},name:Market Intelligence,node_type:section,site:{}},{_id:/generics-bulletin/preview,children:,name:Preview,node_type:section,site:{}},{_id:/generics-bulletin/esg,children:,name:ESG,node_type:section,site:{}},{_id:/generics-bulletin/conferences,children:{_id:/generics-bulletin/conferences/AAM,children:,name:AAM,node_type:section,site:{}},{_id:/generics-bulletin/conferences/IGBA,children:,name:IGBA,node_type:section,site:{}},{_id:/generics-bulletin/conferences/medicines-for-europe,children:,name:Medicines for Europe,node_type:section,site:{}},name:Conferences,node_type:section,site:{}},{_id:/generics-bulletin/podcasts,children:,name:Podcasts,node_type:section,site:{}},{_id:link-NU724CQSCZDVNGJ2DVXWWWYXTQ,children:,display_name:Partnered Content,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/partnered-content/},{_id:link-WSF6RL4HNZB4XPJ6MAXMTV6KPM,children:,display_name:Perspectives,node_type:link,url:/generics-bulletin/perspectives},name:Generics Bulletin,node_type:section,site:{}},{_id:/hbw-insight,children:{_id:/hbw-insight/health,children:{_id:/hbw-insight/health/policy-and-regulation,children:,name:Policy & Regulation,node_type:section,site:{}},{_id:/hbw-insight/health/business,children:,name:Business,node_type:section,site:{}},name:Health,node_type:section,site:{}},{_id:/hbw-insight/beauty,children:{_id:/hbw-insight/beauty/policy-and-regulation,children:,name:Policy & Regulation,node_type:section,site:{}},{_id:/hbw-insight/beauty/business,children:,name:Business,node_type:section,site:{}},name:Beauty,node_type:section,site:{}},{_id:/hbw-insight/wellness,children:{_id:/hbw-insight/wellness/policy-and-regulation,children:,name:Policy & Regulation,node_type:section,site:{}},{_id:/hbw-insight/wellness/business,children:,name:Business,node_type:section,site:{}},name:Wellness,node_type:section,site:{}},{_id:/hbw-insight/leadership,children:,name:Leadership,node_type:section,site:{}},{_id:/hbw-insight/ingredients-and-safety,children:,name:Ingredients & Safety,node_type:section,site:{}},{_id:link-EGBBRTDUIFCS7OFY7MGBN655EU,children:,display_name:Perspectives,node_type:link,url:/hbw-insight/perspectives},{_id:/hbw-insight/digital-technologies,children:,name:Digital Technologies,node_type:section,site:{}},{_id:/hbw-insight/esg,children:,name:ESG,node_type:section,site:{}},{_id:/hbw-insight/podcasts,children:,name:Podcasts,node_type:section,site:{}},{_id:/hbw-insight/conferences,children:,name:Conferences,node_type:section,site:{}},{_id:link-R4WJU4HM5ZH2DNLLAFK5IUPM5E,children:,display_name:Partnered Content,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/partnered-content/},name:HBW Insight,node_type:section,site:{}},{_id:/medtech-insight,children:{_id:/medtech-insight/policy-and-regulation,children:,name:Policy & Regulation,node_type:section,site:{}},{_id:/medtech-insight/business,children:,name:Business,node_type:section,site:{}},{_id:/medtech-insight/market-access,children:,name:Market Access,node_type:section,site:{}},{_id:/medtech-insight/leadership,children:,name:Leadership,node_type:section,site:{}},{_id:/medtech-insight/podcasts,children:,name:Podcasts,node_type:section,site:{}},{_id:/medtech-insight/digital-technologies,children:,name:Digital Technologies,node_type:section,site:{}},{_id:/medtech-insight/esg,children:,name:ESG,node_type:section,site:{}},{_id:/medtech-insight/market-intelligence,children:{_id:/medtech-insight/market-intelligence/company-rankings,children:,name:Company Rankings,node_type:section,site:{}},name:Market Intelligence,node_type:section,site:{}},{_id:/medtech-insight/conferences,children:,name:Conferences,node_type:section,site:{}},{_id:link-BGVLNIBLJBF6HEQ52QS7OSPAUA,children:,display_name:Partnered Content,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/partnered-content/},{_id:link-R7R7QHNHLFAWPPJR674CVTCYXU,children:,display_name:Medtech Insight Perspectives,node_type:link,url:/medtech-insight/perspectives},name:Medtech Insight,node_type:section,site:{}},{_id:/pink-sheet,children:{_id:/pink-sheet/regulatory-trackers,children:{_id:/pink-sheet/regulatory-trackers/global-pharma-guidance-update,children:,name:Global Pharma Guidance Update,node_type:section,site:{}},{_id:/pink-sheet/regulatory-trackers/european-performance-tracker,children:{_id:link-TFY5P6CJIJFZFJRR35FWOV5TUQ,children:,display_name:EU Filings,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/pink-sheet/regulatory-trackers/european-performance-tracker/new-eu-filings/},{_id:link-QBQOCWG4BNB3TL45OWLVAT6PGQ,children:,display_name:EU CHMP Opinions & MAA Updates,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/pink-sheet/regulatory-trackers/european-performance-tracker/eu-chmp-opinions-maa-updates/},{_id:link-KLHCQZIXEZDZFHXSLPVMNOEQRY,children:,display_name:EU Approvals,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/pink-sheet/regulatory-trackers/european-performance-tracker/eu-approvals/},{_id:link-5OVLFKKU2JCS5O5PYH3BUDZXGA,children:,display_name:EU Accelerated Assessment Tracker,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/pink-sheet/regulatory-trackers/european-performance-tracker/eu-accelerated-assessment-tracker/},{_id:link-BA2VO7J2NFHJDK6ZUPB7HWTFJI,children:,display_name:EU Biosimilar Filings, Opinions & Approvals,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/pink-sheet/regulatory-trackers/european-performance-tracker/eu-biosimilar-filings-opinions-approvals/},{_id:link-KACDEM5YOZEGVPGJLSEAKLJQP4,children:,display_name:EMA PRIME Scheme,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/pink-sheet/regulatory-trackers/european-performance-tracker/ema-prime-scheme/},name:European Performance Tracker,node_type:section,site:{}},{_id:/pink-sheet/regulatory-trackers/us-fda-performance-tracker,children:{_id:link-G2AM67OLZ5FKDGXP6HWHAVEPLA,children:,display_name:User Fee Goal Dates,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/pink-sheet/regulatory-trackers/us-fda-performance-tracker/user-fee-goal-dates/},{_id:link-ITZCZOUZAZD2TGEYRWF75ZYTTM,children:,display_name:CDER Novel Approvals,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/pink-sheet/regulatory-trackers/us-fda-performance-tracker/cder-novel-approvals/},{_id:link-JQ46Y5FTC5CELELVHLG2A5DUMU,children:,display_name:CBER Novel Approvals,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/pink-sheet/regulatory-trackers/us-fda-performance-tracker/cber-novel-approvals/},{_id:link-TOBMSZC6EFHPBIB4OXSUIBWQDY,children:,display_name:Breakthrough Designations,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/pink-sheet/regulatory-trackers/us-fda-performance-tracker/breakthrough-therapy-designations/},{_id:link-OYDVD6OKXZADTMLZAXLM235RY4,children:,display_name:RMAT Designations,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/pink-sheet/regulatory-trackers/us-fda-performance-tracker/regenerative-medicine-advanced-therapies/},{_id:link-RWBXNEOTSBEXJAPPOB4TN4EFFU,children:,display_name:QIDP Designations,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/pink-sheet/regulatory-trackers/us-fda-performance-tracker/qualified-infectious-disease-products/},{_id:link-47NIIQAMORDF7AD7Y7Q5GAHSN4,children:,display_name:Biosimilars,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/pink-sheet/regulatory-trackers/us-fda-performance-tracker/us-biosimilars/},{_id:link-H3JO37HHAFGVHDX3YS6VGXVPOY,children:,display_name:Complete Response Letters,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/pink-sheet/regulatory-trackers/us-fda-performance-tracker/complete-response-letters/},{_id:link-6I2K44RHKVE7PFHX5P3K2PQJ5Y,children:,display_name:Advisory Committees,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/pink-sheet/regulatory-trackers/us-fda-performance-tracker/fda-advisory-committee-meetings/},name:US FDA Performance Tracker,node_type:section,site:{}},name:Regulatory Trackers,node_type:section,site:{}},{_id:/pink-sheet/regional-comparisons,children:,name:Regional Comparisons,node_type:section,site:{}},{_id:/pink-sheet/interviews,children:,name:Interviews,node_type:section,site:{}},{_id:/pink-sheet/pink-sheet-perspectives,children:,name:Pink Sheet Perspectives,node_type:section,site:{}},{_id:/pink-sheet/pathways-and-standards,children:,name:Pathways & Standards,node_type:section,site:{}},{_id:/pink-sheet/product-reviews,children:,name:Product Reviews ,node_type:section,site:{}},{_id:/pink-sheet/agency-leadership,children:,name:Agency Leadership,node_type:section,site:{}},{_id:/pink-sheet/drug-safety,children:,name:Drug Safety,node_type:section,site:{}},{_id:/pink-sheet/market-access,children:,name:Market Access,node_type:section,site:{}},{_id:/pink-sheet/legislation,children:,name:Legislation,node_type:section,site:{}},{_id:/pink-sheet/legalandip,children:,name:Legal & IP,node_type:section,site:{}},{_id:/pink-sheet/compliance,children:,name:Compliance,node_type:section,site:{}},{_id:/pink-sheet/r-and-d,children:,name:R&D,node_type:section,site:{}},{_id:/pink-sheet/rare-diseases,children:,name:Rare Diseases,node_type:section,site:{}},{_id:/pink-sheet/vaccines,children:,name:Vaccines,node_type:section,site:{}},{_id:/pink-sheet/advanced-technologies,children:,name:Advanced Technologies,node_type:section,site:{}},{_id:/pink-sheet/biosimilars-and-generics,children:,name:Biosimilars & Generics,node_type:section,site:{}},{_id:/pink-sheet/conferences,children:,name:Conferences,node_type:section,site:{}},{_id:/pink-sheet/podcasts,children:,name:Podcasts,node_type:section,site:{}},{_id:link-ZB6QMNX5K5BUBGDIDHX6SJ4FCM,children:,display_name:Partnered Content,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/partnered-content/},name:Pink Sheet,node_type:section,site:{}},{_id:/scrip,children:{_id:/scrip/business,children:{_id:/scrip/business/deals,children:,name:Deals,node_type:section,site:{}},{_id:/scrip/business/financing,children:,name:Financing,node_type:section,site:{}},{_id:/scrip/business/earnings,children:,name:Earnings,node_type:section,site:{}},{_id:/scrip/business/start-ups-and-smes,children:,name:Start-Ups & SMEs,node_type:section,site:{}},{_id:/scrip/business/stock-watch,children:,name:Stock Watch,node_type:section,site:{}},name:Business,node_type:section,site:{}},{_id:/scrip/leadership,children:{_id:/scrip/leadership/executives-on-the-move,children:,name:Executives On The Move,node_type:section,site:{}},{_id:/scrip/leadership/interviews,children:,name:Interviews,node_type:section,site:{}},name:Leadership ,node_type:section,site:{}},{_id:/scrip/r-and-d,children:{_id:/scrip/r-and-d/clinical-trials,children:,name:Clinical Trials,node_type:section,site:{}},{_id:/scrip/r-and-d/pipeline-watch,children:,name:Pipeline Watch,node_type:section,site:{}},name:R&D,node_type:section,site:{}},{_id:/scrip/new-products,children:,name:New Products,node_type:section,site:{}},{_id:/scrip/therapeutic-category,children:,name:Therapeutic Category,node_type:section,site:{}},{_id:/scrip/advanced-therapies,children:,name:Advanced Therapies,node_type:section,site:{}},{_id:/scrip/digital-technologies,children:{_id:/scrip/digital-technologies/ai,children:,name:AI,node_type:section,site:{}},name:Digital Technologies,node_type:section,site:{}},{_id:/scrip/rare-diseases,children:,name:Rare Diseases,node_type:section,site:{}},{_id:/scrip/womens-health,children:,name:Womens Health,node_type:section,site:{}},{_id:/scrip/drug-pricing,children:,name:Drug Pricing,node_type:section,site:{}},{_id:/scrip/esg,children:,name:ESG,node_type:section,site:{}},{_id:/scrip/conferences,children:,name:Conferences,node_type:section,site:{}},{_id:/scrip/focus-on-asia,children:{_id:/scrip/focus-on-asia/scrip-asia-100,children:,name:Scrip Asia 100,node_type:section,site:{}},name:Focus On Asia,node_type:section,site:{}},{_id:/scrip/perspectives,children:,name:Scrip Perspectives,node_type:section,site:{}},{_id:/scrip/scrip-asks,children:,name:Scrip Asks,node_type:section,site:{}},{_id:/scrip/market-snapshot,children:,name:Market Snapshot,node_type:section,site:{}},{_id:/scrip/podcasts,children:,name:Podcasts,node_type:section,site:{}},{_id:link-72XXRUMF7RFBTIFZGHCHGYIAP4,children:,display_name:Partnered Content,node_type:link,url:https://norstella-insights-sandbox.web.arc-cdn.net/partnered-content/},name:Scrip,node_type:section,site:{}},{_id:/pink-sheet/deepeshtest,children:,name:Deepesh-test,navigation:{clickable:true},node_type:section,site:{site_url:deepeshtest}},_id:/},expires:1768674857969,lastModified:1768674557865},{\feature\:\links-bar\,\hierarchy\:\fast_access\}:{data:{children:{_id:/pink-sheet,children:{_id:/pink-sheet/pathways-and-standards,name:Pathways & Standards,node_type:section},{_id:/pink-sheet/product-reviews,name:Product Reviews ,node_type:section},{_id:/pink-sheet/agency-leadership,name:Agency Leadership,node_type:section},{_id:/pink-sheet/market-access,name:Market Access,node_type:section},{_id:/pink-sheet/r-and-d,name:R&D,node_type:section},{_id:/pink-sheet/podcasts,name:Podcasts,node_type:section},name:Pink Sheet,node_type:section},{_id:/scrip,children:{_id:/scrip/business,name:Business,node_type:section},{_id:/scrip/leadership,name:Leadership ,node_type:section},{_id:/scrip/r-and-d,name:R&D,node_type:section},{_id:/scrip/new-products,name:New Products,node_type:section},{_id:/scrip/drug-pricing,name:Drug Pricing,node_type:section},{_id:/scrip/podcasts,name:Podcasts,node_type:section},name:Scrip,node_type:section},{_id:/medtech-insight,children:{_id:/medtech-insight/policy-and-regulation,name:Policy & Regulation,node_type:section},{_id:/medtech-insight/business,name:Business,node_type:section},{_id:/medtech-insight/digital-technologies,name:Digital Technologies,node_type:section},{_id:/medtech-insight/market-intelligence,name:Market Intelligence,node_type:section},{_id:/medtech-insight/podcasts,name:Podcasts,node_type:section},name:Medtech Insight,node_type:section},{_id:/hbw-insight,children:{_id:/hbw-insight/health,name:Health,node_type:section},{_id:/hbw-insight/beauty,name:Beauty,node_type:section},{_id:/hbw-insight/wellness,name:Wellness,node_type:section},{_id:/hbw-insight/leadership,name:Leadership,node_type:section},{_id:/hbw-insight/perspectives,name:Perspectives,node_type:section},{_id:/hbw-insight/podcasts,name:Podcasts,node_type:section},name:HBW Insight,node_type:section},{_id:/generics-bulletin,children:{_id:/generics-bulletin/business,name:Business,node_type:section},{_id:/generics-bulletin/leadership,name:Leadership,node_type:section},{_id:/generics-bulletin/policy-and-regulation,name:Policy & Regulation,node_type:section},{_id:/generics-bulletin/legalandip,name:Legal & IP,node_type:section},{_id:/generics-bulletin/products,name:Products,node_type:section},{_id:/generics-bulletin/perspectives,name:Perspectives,node_type:section},{_id:/generics-bulletin/podcasts,name:Podcasts,node_type:section},name:Generics Bulletin,node_type:section},{_id:/in-vivo,children:{_id:/in-vivo/innovation,name:Innovation,node_type:section},{_id:/in-vivo/growth,name:Growth,node_type:section},{_id:/in-vivo/market-access,name:Market Access,node_type:section},{_id:/in-vivo/market-intelligence,name:Market Intelligence,node_type:section},{_id:/in-vivo/outlook,name:Outlook,node_type:section},{_id:/in-vivo/podcasts,name:Podcasts,node_type:section},name:In Vivo,node_type:section},_id:/},expires:1768674652790,lastModified:1768674352725},{\feature\:\footer\,\hierarchy\:\footer\}:{data:{children:{_id:/about-us,children:{_id:link-BKNNWFITUVBFNHMQN6CUPKWHPI,display_name:About Us,node_type:link,url:https://www.citeline.com/en/solutions/news-and-insights},{_id:link-HBRHGIZM4VBKRB7USCE4GF3QWU,display_name:Meet the Team,node_type:link,url:/meet-the-team/},{_id:link-2TDPTWA6HBGYZAM5OHXBTAYBAE,display_name:Advertise,node_type:link,url:https://www.citeline.com/en/products-services/marketing/pharma-ignite},{_id:link-YAELMME2GBCEBJ4HOLLCB4BREQ,display_name:Contact Us,node_type:link,url:/contact-us/},name:About,node_type:section},{_id:/account,children:{_id:link-HLF5MZJDKZBIDD4LMQZGAAYZ3I,display_name:My Account,node_type:link,url:/my-account/contact-information/},{_id:link-D2FGL36LSRGQPHJPJNC6JM2JVA,display_name:My View,node_type:link,url:/my-view-page/},{_id:link-YR7NDWBRYNFYZCPY5RLBBPIFK4,display_name:Email Preferences,node_type:link,url:/my-account/email-preferences/},{_id:link-MIDHGOQ2OBBZ7M4A2IE3QWIFSE,display_name:Start Free Trial,node_type:link,url:https://www.citeline.com/en/app-insights-trial},name:Account,node_type:section},{_id:/publications,children:{_id:/pink-sheet,name:Pink Sheet,node_type:section},{_id:/scrip,name:Scrip,node_type:section},{_id:/medtech-insight,name:Medtech Insight,node_type:section},{_id:/hbw-insight,name:HBW Insight,node_type:section},{_id:/generics-bulletin,name:Generics Bulletin,node_type:section},{_id:/in-vivo,name:In Vivo,node_type:section},name:Publications,node_type:section},_id:/},expires:1768674716031,lastModified:1768674415980}},story-feed-sections:{{\feature\:\results-list\,\feedOffset\:0,\feedSize\:8,\includeSections\:\/scrip, /medtech-insight, /in-vivo, /pink-sheet, /hbw-insight, /generics-bulletin\}:{data:{content_elements:{_id:XL7YDJHZZNH4DOBDZRXW44KSOM,canonical_url:/generics-bulletin/test-article-XL7YDJHZZNH4DOBDZRXW44KSOM/,content_elements:{},{},{},credits:{by:{_id:reed-miller,additional_properties:{original:{byline:Reed Miller}},name:Reed Miller,type:author,url:/authors/reed-miller}},description:{basic:Thermo Fisher Scientific was one of the first companies in its peer group to have its near and long-term net-zero targets validated by the Science Based Targets initiative (SBTi).},display_date:2026-01-13T13:07:45.991Z,headlines:{basic:Test article},owner:{sponsored:false},subtype:Article,taxonomy:{primary_section:{_id:/generics-bulletin}},type:story,website_url:/generics-bulletin/test-article-XL7YDJHZZNH4DOBDZRXW44KSOM/,websites:{insights:{website_section:{_id:/generics-bulletin,name:Generics Bulletin},website_url:/generics-bulletin/test-article-XL7YDJHZZNH4DOBDZRXW44KSOM/}}},{_id:YGKCRTDJKNJSXEBXKUQJMOIKAY,canonical_url:/PS154848/COVID-Vaccines-US-FDA-Changes-Course-Wants-New-Formulas-To-Target-KP2-Subvariant-If-Feasible/,content_elements:{},{},{embed:{config:{}},subtype:quick_facts},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{subtype:pullquote},{},{},{},{},{},{},{},{subtype:pullquote},{},{},{},{},{},{},{},{},{},{},{},{},{},credits:{by:{_id:sue-sutter,additional_properties:{original:{byline:Sue Sutter}},name:Sue Sutter,type:author,url:/authors/sue-sutter}},description:{basic:Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’},display_date:2026-01-05T09:28:26.952Z,headlines:{basic:COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’},owner:{sponsored:false},subtype:Analysis,taxonomy:{primary_section:{_id:/pink-sheet/vaccines}},type:story,website_url:/PS154848/COVID-Vaccines-US-FDA-Changes-Course-Wants-New-Formulas-To-Target-KP2-Subvariant-If-Feasible/,websites:{insights:{website_section:{_id:/pink-sheet/vaccines,name:Vaccines},website_url:/PS154848/COVID-Vaccines-US-FDA-Changes-Course-Wants-New-Formulas-To-Target-KP2-Subvariant-If-Feasible/}}},{_id:KN4S6IU65JF35EZHKXV232KAOM,canonical_url:/generics-bulletin/business/covid-searches-KN4S6IU65JF35EZHKXV232KAOM/,content_elements:{},{},{},{},{},{},display_date:2026-01-05T08:56:03.729Z,headlines:{basic:Covid searches},owner:{sponsored:false},subtype:Article,taxonomy:{primary_section:{_id:/generics-bulletin/business}},type:story,website_url:/generics-bulletin/business/covid-searches-KN4S6IU65JF35EZHKXV232KAOM/,websites:{insights:{website_section:{_id:/generics-bulletin/business,name:Business},website_url:/generics-bulletin/business/covid-searches-KN4S6IU65JF35EZHKXV232KAOM/}}},{_id:UEZLL73UQNDRNEUGKSTMSAFZPY,canonical_url:/pink-sheet/podcasts/nancy-tests-new-podcast-template-UEZLL73UQNDRNEUGKSTMSAFZPY/,content_elements:{},{},{},{},{},{},{},credits:{by:{_id:derrick-gingery,additional_properties:{original:{byline:Derrick Gingery}},name:Derrick Gingery,type:author,url:/authors/derrick-gingery}},description:{basic:Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.\r\n},display_date:2025-12-16T13:38:29.713Z,headlines:{basic:Nancy Tests New Podcast Template},owner:{sponsored:false},promo_items:{basic:{_id:RYW7642ZYRLN7P6PWMG5PI7I7Q,auth:{1:fd8c4368d739d59f5ebf880cbca5ca7cad7160a9e5caefd0a68447b742126456},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/RYW7642ZYRLN7P6PWMG5PI7I7Q.png}},subtype:Podcast,taxonomy:{primary_section:{_id:/pink-sheet/podcasts}},type:story,website_url:/pink-sheet/podcasts/nancy-tests-new-podcast-template-UEZLL73UQNDRNEUGKSTMSAFZPY/,websites:{insights:{website_section:{_id:/pink-sheet/podcasts,name:Podcasts},website_url:/pink-sheet/podcasts/nancy-tests-new-podcast-template-UEZLL73UQNDRNEUGKSTMSAFZPY/}}},{_id:ZMOJPDF67BGDTGPHDP5T222TXE,canonical_url:/generics-bulletin/podcasts/podcast-subtype-sample-vigya-ZMOJPDF67BGDTGPHDP5T222TXE/,content_elements:{},{},{},{},{},{},{},credits:{by:{_id:ian-schofield,additional_properties:{original:{byline:Ian Schofield}},name:Ian Schofield,type:author,url:/authors/ian-schofield}},description:{basic:In this weeks episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimers rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab. },display_date:2025-12-16T09:31:23.662Z,headlines:{basic:Podcast subtype sample-vigya},owner:{sponsored:false},promo_items:{basic:{_id:Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q,auth:{1:83067321da81600860bdc1fc05b6d23dd01fb08e648d4706d36780a0a8f5f377},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q.png}},subtype:Podcast,taxonomy:{primary_section:{_id:/generics-bulletin/podcasts}},type:story,website_url:/generics-bulletin/podcasts/podcast-subtype-sample-vigya-ZMOJPDF67BGDTGPHDP5T222TXE/,websites:{insights:{website_section:{_id:/generics-bulletin/podcasts,name:Podcasts},website_url:/generics-bulletin/podcasts/podcast-subtype-sample-vigya-ZMOJPDF67BGDTGPHDP5T222TXE/}}},{_id:QARSICCAUJEU3KLTHHDWFNIO6M,canonical_url:/pink-sheet/podcasts/pink-sheet-podcast-understanding-the-us-fdas-cder-leadership-shuffle-QARSICCAUJEU3KLTHHDWFNIO6M/,content_elements:{},{},{},{},{},credits:{by:{_id:mary-jo-laffler,additional_properties:{original:{byline:Mary Jo Laffler}},name:Mary Jo Laffler,type:author,url:/authors/mary-jo-laffler}},description:{basic:Pink Sheet reporter and editors discuss the likely impacts of Center for Drug Evaluation and Research Director Richard Pazdur’s retirement from the FDA and Tracy Beth Høeg becoming the center’s acting director.},display_date:2025-12-10T03:26:54.241Z,headlines:{basic:Pink Sheet Podcast: Understanding the US FDA’s CDER Leadership Shuffle },owner:{sponsored:false},promo_items:{basic:{_id:Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q,auth:{1:83067321da81600860bdc1fc05b6d23dd01fb08e648d4706d36780a0a8f5f377},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q.png}},subtype:Podcast,taxonomy:{primary_section:{_id:/pink-sheet/podcasts}},type:story,website_url:/pink-sheet/podcasts/pink-sheet-podcast-understanding-the-us-fdas-cder-leadership-shuffle-QARSICCAUJEU3KLTHHDWFNIO6M/,websites:{insights:{website_section:{_id:/pink-sheet/podcasts,name:Podcasts},website_url:/pink-sheet/podcasts/pink-sheet-podcast-understanding-the-us-fdas-cder-leadership-shuffle-QARSICCAUJEU3KLTHHDWFNIO6M/}}},{_id:ADRPK3O2VJET7LRMHH367XHTFE,canonical_url:/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ADRPK3O2VJET7LRMHH367XHTFE/,content_elements:{},{},{},{},{},{},credits:{by:{_id:reed-miller,additional_properties:{original:{byline:Reed Miller}},name:Reed Miller,type:author,url:/authors/reed-miller}},description:{basic:In this weeks episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimers rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab. },display_date:2025-12-09T18:58:33.274Z,headlines:{basic:Quick Listen: Scrip’s Five Must-Know Things},owner:{sponsored:false},promo_items:{basic:{_id:Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q,auth:{1:83067321da81600860bdc1fc05b6d23dd01fb08e648d4706d36780a0a8f5f377},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q.png}},subtype:Podcast,taxonomy:{primary_section:{_id:/scrip/podcasts/scrips-five-must-know-things}},type:story,website_url:/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ADRPK3O2VJET7LRMHH367XHTFE/,websites:{insights:{website_section:{_id:/scrip/podcasts/scrips-five-must-know-things,name:Scrips Five Must-Know Things},website_url:/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ADRPK3O2VJET7LRMHH367XHTFE/}}},{_id:DRC2QVH7MZFV3JJFX7QIDAVAOQ,canonical_url:/generics-bulletin/archive/embracing-chinas-brave-new-pharmaceutical-world-clone-clone-DRC2QVH7MZFV3JJFX7QIDAVAOQ/,content_elements:{},credits:{by:{name:Ellon Xu,type:author},{name:Philip Leung,type:author},{name:Grace Shieh,type:author}},description:{basic:Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change. },display_date:2025-12-09T10:45:53.703Z,headlines:{basic:Embracing China’s Brave New Pharmaceutical World! - Clone - Clone!},owner:{sponsored:false},subtype:Article,taxonomy:{primary_section:{_id:/generics-bulletin/archive}},type:story,website_url:/generics-bulletin/archive/embracing-chinas-brave-new-pharmaceutical-world-clone-clone-DRC2QVH7MZFV3JJFX7QIDAVAOQ/,websites:{insights:{website_section:{_id:/generics-bulletin/archive,name:Archive},website_url:/generics-bulletin/archive/embracing-chinas-brave-new-pharmaceutical-world-clone-clone-DRC2QVH7MZFV3JJFX7QIDAVAOQ/}}},count:10000,next:8,_id:4fd362f51e9466b0fc3f65e1516188ab8683f50d7ef346916af6e27d819eb3ac},expires:1768674855899,lastModified:1768674555631},{\feature\:\results-list\,\feedOffset\:0,\feedSize\:8,\includeSections\:\/scrip, /pink-sheet\}:{data:{content_elements:{_id:YGKCRTDJKNJSXEBXKUQJMOIKAY,canonical_url:/PS154848/COVID-Vaccines-US-FDA-Changes-Course-Wants-New-Formulas-To-Target-KP2-Subvariant-If-Feasible/,content_elements:{},{},{embed:{config:{}},subtype:quick_facts},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{subtype:pullquote},{},{},{},{},{},{},{},{subtype:pullquote},{},{},{},{},{},{},{},{},{},{},{},{},{},credits:{by:{_id:sue-sutter,additional_properties:{original:{byline:Sue Sutter}},name:Sue Sutter,type:author,url:/authors/sue-sutter}},description:{basic:Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’},display_date:2026-01-05T09:28:26.952Z,headlines:{basic:COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’},owner:{sponsored:false},subtype:Analysis,taxonomy:{primary_section:{_id:/pink-sheet/vaccines}},type:story,website_url:/PS154848/COVID-Vaccines-US-FDA-Changes-Course-Wants-New-Formulas-To-Target-KP2-Subvariant-If-Feasible/,websites:{insights:{website_section:{_id:/pink-sheet/vaccines,name:Vaccines},website_url:/PS154848/COVID-Vaccines-US-FDA-Changes-Course-Wants-New-Formulas-To-Target-KP2-Subvariant-If-Feasible/}}},{_id:UEZLL73UQNDRNEUGKSTMSAFZPY,canonical_url:/pink-sheet/podcasts/nancy-tests-new-podcast-template-UEZLL73UQNDRNEUGKSTMSAFZPY/,content_elements:{},{},{},{},{},{},{},credits:{by:{_id:derrick-gingery,additional_properties:{original:{byline:Derrick Gingery}},name:Derrick Gingery,type:author,url:/authors/derrick-gingery}},description:{basic:Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.\r\n},display_date:2025-12-16T13:38:29.713Z,headlines:{basic:Nancy Tests New Podcast Template},owner:{sponsored:false},promo_items:{basic:{_id:RYW7642ZYRLN7P6PWMG5PI7I7Q,auth:{1:fd8c4368d739d59f5ebf880cbca5ca7cad7160a9e5caefd0a68447b742126456},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/RYW7642ZYRLN7P6PWMG5PI7I7Q.png}},subtype:Podcast,taxonomy:{primary_section:{_id:/pink-sheet/podcasts}},type:story,website_url:/pink-sheet/podcasts/nancy-tests-new-podcast-template-UEZLL73UQNDRNEUGKSTMSAFZPY/,websites:{insights:{website_section:{_id:/pink-sheet/podcasts,name:Podcasts},website_url:/pink-sheet/podcasts/nancy-tests-new-podcast-template-UEZLL73UQNDRNEUGKSTMSAFZPY/}}},{_id:QARSICCAUJEU3KLTHHDWFNIO6M,canonical_url:/pink-sheet/podcasts/pink-sheet-podcast-understanding-the-us-fdas-cder-leadership-shuffle-QARSICCAUJEU3KLTHHDWFNIO6M/,content_elements:{},{},{},{},{},credits:{by:{_id:mary-jo-laffler,additional_properties:{original:{byline:Mary Jo Laffler}},name:Mary Jo Laffler,type:author,url:/authors/mary-jo-laffler}},description:{basic:Pink Sheet reporter and editors discuss the likely impacts of Center for Drug Evaluation and Research Director Richard Pazdur’s retirement from the FDA and Tracy Beth Høeg becoming the center’s acting director.},display_date:2025-12-10T03:26:54.241Z,headlines:{basic:Pink Sheet Podcast: Understanding the US FDA’s CDER Leadership Shuffle },owner:{sponsored:false},promo_items:{basic:{_id:Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q,auth:{1:83067321da81600860bdc1fc05b6d23dd01fb08e648d4706d36780a0a8f5f377},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q.png}},subtype:Podcast,taxonomy:{primary_section:{_id:/pink-sheet/podcasts}},type:story,website_url:/pink-sheet/podcasts/pink-sheet-podcast-understanding-the-us-fdas-cder-leadership-shuffle-QARSICCAUJEU3KLTHHDWFNIO6M/,websites:{insights:{website_section:{_id:/pink-sheet/podcasts,name:Podcasts},website_url:/pink-sheet/podcasts/pink-sheet-podcast-understanding-the-us-fdas-cder-leadership-shuffle-QARSICCAUJEU3KLTHHDWFNIO6M/}}},{_id:ADRPK3O2VJET7LRMHH367XHTFE,canonical_url:/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ADRPK3O2VJET7LRMHH367XHTFE/,content_elements:{},{},{},{},{},{},credits:{by:{_id:reed-miller,additional_properties:{original:{byline:Reed Miller}},name:Reed Miller,type:author,url:/authors/reed-miller}},description:{basic:In this weeks episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimers rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab. },display_date:2025-12-09T18:58:33.274Z,headlines:{basic:Quick Listen: Scrip’s Five Must-Know Things},owner:{sponsored:false},promo_items:{basic:{_id:Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q,auth:{1:83067321da81600860bdc1fc05b6d23dd01fb08e648d4706d36780a0a8f5f377},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q.png}},subtype:Podcast,taxonomy:{primary_section:{_id:/scrip/podcasts/scrips-five-must-know-things}},type:story,website_url:/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ADRPK3O2VJET7LRMHH367XHTFE/,websites:{insights:{website_section:{_id:/scrip/podcasts/scrips-five-must-know-things,name:Scrips Five Must-Know Things},website_url:/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ADRPK3O2VJET7LRMHH367XHTFE/}}},{_id:DSLA7GV4PNOI7K4KRAZKIWDBBM,canonical_url:/SC150682/ProGens-Dual-Agonist-Obesity-Contender-Gains-Momentum-With-Rani-Partnership/,content_elements:{},{},{},{embed:{config:{}},subtype:quick_facts},{},{},{},{},{},{},{},{},{},{},{},{subtype:pullquote},{},{},{},{},{},{},{},{},credits:{by:{_id:jung-won-shin,additional_properties:{original:{byline:Jung Won Shin}},name:Jung Won Shin,type:author,url:/authors/jung-won-shin}},description:{basic:The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.},display_date:2025-12-05T17:16:12.993Z,headlines:{basic:ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership},owner:{sponsored:false},promo_items:{basic:{_id:WBXKDKYGONMSJPAXQJEJBOEJZA,auth:{1:17a04e96c9474c84da141d36877aece5218db82598dce16558ce0dedb40598be},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/WBXKDKYGONMSJPAXQJEJBOEJZA.jpg}},subtype:Interview,taxonomy:{primary_section:{_id:/scrip/therapeutic-category/alimentary-metabolic}},type:story,website_url:/SC150682/ProGens-Dual-Agonist-Obesity-Contender-Gains-Momentum-With-Rani-Partnership/,websites:{insights:{website_section:{_id:/scrip/therapeutic-category/alimentary-metabolic,name:Alimentary/Metabolic},website_url:/SC150682/ProGens-Dual-Agonist-Obesity-Contender-Gains-Momentum-With-Rani-Partnership/}}},{_id:MSGF7XPN45I6LDOMNA4EEPZZNI,canonical_url:/SC087726/Embracing-Chinas-Brave-New-Pharmaceutical-World/,content_elements:{},credits:{by:{name:Ellon Xu,type:author},{name:Philip Leung,type:author},{name:Grace Shieh,type:author}},description:{basic:Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change. },display_date:2025-12-05T16:54:09.193Z,headlines:{basic:Embracing China’s Brave New Pharmaceutical World!},owner:{sponsored:false},subtype:Article,taxonomy:{primary_section:{_id:/scrip/focus-on-asia/china}},type:story,website_url:/SC087726/Embracing-Chinas-Brave-New-Pharmaceutical-World/,websites:{insights:{website_section:{_id:/scrip/focus-on-asia/china,name:China},website_url:/SC087726/Embracing-Chinas-Brave-New-Pharmaceutical-World/}}},{_id:HY7YKK22W5N2TLE4FJ33ES6UN4,canonical_url:/SC151026/Sciwind-Eyes-Differentiation-For-Ecnoglutide-In-Highly-Competitive-Arena/,content_elements:{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{embed:{config:{}},subtype:files_upload},{},credits:{by:{_id:xu-hu,additional_properties:{original:{byline:Xu Hu}},name:Xu Hu,type:author,url:/authors/xu-hu}},description:{basic:Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes. },display_date:2025-12-05T15:40:19.611Z,headlines:{basic:Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena},owner:{sponsored:false},promo_items:{basic:{_id:C54CWHH2GBJ7TGWUQ22PICJIKI,auth:{1:81e9fdfca5ce93f053204b6bfe8544e85ad35d5e467b6b0c65dedfe0b09b31f2},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/C54CWHH2GBJ7TGWUQ22PICJIKI.jpg}},subtype:Analysis,taxonomy:{primary_section:{_id:/scrip/r-and-d/clinical-trials}},type:story,website_url:/SC151026/Sciwind-Eyes-Differentiation-For-Ecnoglutide-In-Highly-Competitive-Arena/,websites:{insights:{website_section:{_id:/scrip/r-and-d/clinical-trials,name:Clinical Trials},website_url:/SC151026/Sciwind-Eyes-Differentiation-For-Ecnoglutide-In-Highly-Competitive-Arena/}}},{_id:5O7INJQELVBNZLF66B5P77ZJBU,canonical_url:/scrip/r-and-d/clinical-trials/fosun-alkros1-inhibitor-shows-1l-promise-in-advanced-nsclc-5O7INJQELVBNZLF66B5P77ZJBU/,content_elements:{},{},{},{},{},{},{},{},{},{},{},{},{},credits:{by:{additional_properties:{original:{}},name:Xu Hu,type:author}},description:{basic:Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.},display_date:2025-12-05T15:03:33.611Z,headlines:{basic:Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC},owner:{sponsored:false},subtype:Article,taxonomy:{primary_section:{_id:/scrip/r-and-d/clinical-trials}},type:story,website_url:/scrip/r-and-d/clinical-trials/fosun-alkros1-inhibitor-shows-1l-promise-in-advanced-nsclc-5O7INJQELVBNZLF66B5P77ZJBU/,websites:{insights:{website_section:{_id:/scrip/r-and-d/clinical-trials,name:Clinical Trials},website_url:/scrip/r-and-d/clinical-trials/fosun-alkros1-inhibitor-shows-1l-promise-in-advanced-nsclc-5O7INJQELVBNZLF66B5P77ZJBU/}}},count:10000,next:8,_id:481da775fcf1f87f93dc9b97dbd07c0e3289cbeae6ea430c7bb78efa038c1cb2},expires:1768674855872,lastModified:1768674555625},{\feature\:\results-list\,\feedOffset\:0,\feedSize\:8,\includeSections\:\/medtech-insight, /in-vivo, /hbw-insight, /generics-bulletin\}:{data:{content_elements:{_id:XL7YDJHZZNH4DOBDZRXW44KSOM,canonical_url:/generics-bulletin/test-article-XL7YDJHZZNH4DOBDZRXW44KSOM/,content_elements:{},{},{},credits:{by:{_id:reed-miller,additional_properties:{original:{byline:Reed Miller}},name:Reed Miller,type:author,url:/authors/reed-miller}},description:{basic:Thermo Fisher Scientific was one of the first companies in its peer group to have its near and long-term net-zero targets validated by the Science Based Targets initiative (SBTi).},display_date:2026-01-13T13:07:45.991Z,headlines:{basic:Test article},owner:{sponsored:false},subtype:Article,taxonomy:{primary_section:{_id:/generics-bulletin}},type:story,website_url:/generics-bulletin/test-article-XL7YDJHZZNH4DOBDZRXW44KSOM/,websites:{insights:{website_section:{_id:/generics-bulletin,name:Generics Bulletin},website_url:/generics-bulletin/test-article-XL7YDJHZZNH4DOBDZRXW44KSOM/}}},{_id:KN4S6IU65JF35EZHKXV232KAOM,canonical_url:/generics-bulletin/business/covid-searches-KN4S6IU65JF35EZHKXV232KAOM/,content_elements:{},{},{},{},{},{},display_date:2026-01-05T08:56:03.729Z,headlines:{basic:Covid searches},owner:{sponsored:false},subtype:Article,taxonomy:{primary_section:{_id:/generics-bulletin/business}},type:story,website_url:/generics-bulletin/business/covid-searches-KN4S6IU65JF35EZHKXV232KAOM/,websites:{insights:{website_section:{_id:/generics-bulletin/business,name:Business},website_url:/generics-bulletin/business/covid-searches-KN4S6IU65JF35EZHKXV232KAOM/}}},{_id:ZMOJPDF67BGDTGPHDP5T222TXE,canonical_url:/generics-bulletin/podcasts/podcast-subtype-sample-vigya-ZMOJPDF67BGDTGPHDP5T222TXE/,content_elements:{},{},{},{},{},{},{},credits:{by:{_id:ian-schofield,additional_properties:{original:{byline:Ian Schofield}},name:Ian Schofield,type:author,url:/authors/ian-schofield}},description:{basic:In this weeks episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimers rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab. },display_date:2025-12-16T09:31:23.662Z,headlines:{basic:Podcast subtype sample-vigya},owner:{sponsored:false},promo_items:{basic:{_id:Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q,auth:{1:83067321da81600860bdc1fc05b6d23dd01fb08e648d4706d36780a0a8f5f377},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q.png}},subtype:Podcast,taxonomy:{primary_section:{_id:/generics-bulletin/podcasts}},type:story,website_url:/generics-bulletin/podcasts/podcast-subtype-sample-vigya-ZMOJPDF67BGDTGPHDP5T222TXE/,websites:{insights:{website_section:{_id:/generics-bulletin/podcasts,name:Podcasts},website_url:/generics-bulletin/podcasts/podcast-subtype-sample-vigya-ZMOJPDF67BGDTGPHDP5T222TXE/}}},{_id:DRC2QVH7MZFV3JJFX7QIDAVAOQ,canonical_url:/generics-bulletin/archive/embracing-chinas-brave-new-pharmaceutical-world-clone-clone-DRC2QVH7MZFV3JJFX7QIDAVAOQ/,content_elements:{},credits:{by:{name:Ellon Xu,type:author},{name:Philip Leung,type:author},{name:Grace Shieh,type:author}},description:{basic:Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change. },display_date:2025-12-09T10:45:53.703Z,headlines:{basic:Embracing China’s Brave New Pharmaceutical World! - Clone - Clone!},owner:{sponsored:false},subtype:Article,taxonomy:{primary_section:{_id:/generics-bulletin/archive}},type:story,website_url:/generics-bulletin/archive/embracing-chinas-brave-new-pharmaceutical-world-clone-clone-DRC2QVH7MZFV3JJFX7QIDAVAOQ/,websites:{insights:{website_section:{_id:/generics-bulletin/archive,name:Archive},website_url:/generics-bulletin/archive/embracing-chinas-brave-new-pharmaceutical-world-clone-clone-DRC2QVH7MZFV3JJFX7QIDAVAOQ/}}},{_id:ML5ZTU22SRLRRGY3XMCGK6HUBI,canonical_url:/MT155075/Digital-Health-Roundup-Digital-Therapeutics-Navigate-GLP1-Immersive-Gaming-DHCoE-AI-Framework-Hello-Heart/,content_elements:{},{subtype:soundcloud},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},credits:{by:},description:{basic:In this week’s Digital Health Roundup, Medtech Insight’s Ryan Nelson highlights Click Therapeutics’ FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics’ personalized neuromodulation for Alzheimer’s patients. Marion Webb discusses her interview with MindMaze’s John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart’s new symptom-tracking feature in their heart-focused app. },display_date:2025-12-08T07:24:56.354Z,headlines:{basic:Digital Health Roundup: Digital Therapeutics Navigate GLP-1, Immersive Gaming; DHCoE AI Framework; Hello Heart},owner:{sponsored:false},promo_items:{basic:{_id:HW7VBRD5FFP3PGUYPJYBIIASXI,auth:{1:60afb493a6803513d7485edea71d77525122aa258fa8ea5f432399c9b764dfe6},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/HW7VBRD5FFP3PGUYPJYBIIASXI.jpg}},subtype:Podcast,taxonomy:{primary_section:{_id:/medtech-insight/podcasts/digital-health-roundup}},type:story,website_url:/MT155075/Digital-Health-Roundup-Digital-Therapeutics-Navigate-GLP1-Immersive-Gaming-DHCoE-AI-Framework-Hello-Heart/,websites:{insights:{website_section:{_id:/medtech-insight/podcasts/digital-health-roundup,name:Digital Health Roundup},website_url:/MT155075/Digital-Health-Roundup-Digital-Therapeutics-Navigate-GLP1-Immersive-Gaming-DHCoE-AI-Framework-Hello-Heart/}}},{_id:O5TE7SRL2RFLRNTKBTXHZG622U,canonical_url:/generics-bulletin/archive/testing-biome-vigya-O5TE7SRL2RFLRNTKBTXHZG622U/,content_elements:{},{},{},{},{},{},{},credits:{by:{_id:reed-miller,additional_properties:{original:{byline:Reed Miller}},name:Reed Miller,type:author,url:/authors/reed-miller}},display_date:2025-12-08T07:19:36.404Z,headlines:{basic:Testing biome-vigya},label:{badges:{display:true,text:breaking news,url:}},owner:{sponsored:false},subtype:Company,taxonomy:{primary_section:{_id:/generics-bulletin/archive}},type:story,website_url:/generics-bulletin/archive/testing-biome-vigya-O5TE7SRL2RFLRNTKBTXHZG622U/,websites:{insights:{website_section:{_id:/generics-bulletin/archive,name:Archive},website_url:/generics-bulletin/archive/testing-biome-vigya-O5TE7SRL2RFLRNTKBTXHZG622U/}}},{_id:DBH2HFA4JJHH3I6INTPLZYLD5I,canonical_url:/generics-bulletin/business/testing-vigya-DBH2HFA4JJHH3I6INTPLZYLD5I/,content_elements:{},{},{},{},{},{},{embed:{config:{companyName:,companyUrl:,images:RUZVUEH5RJBVXMJVHDOJFLP6TE,title:Sponsored by}},subtype:sponsored_by},{},credits:{by:{_id:brian-bossetta,additional_properties:{original:{byline:Brian Bossetta}},name:Brian Bossetta,type:author,url:/authors/brian-bossetta}},display_date:2025-12-08T06:45:12.92Z,headlines:{basic:Testing vigya},label:{badges:{display:true,text:breaking news,url:}},owner:{sponsored:false},subtype:Article,taxonomy:{primary_section:{_id:/generics-bulletin/business}},type:story,website_url:/generics-bulletin/business/testing-vigya-DBH2HFA4JJHH3I6INTPLZYLD5I/,websites:{insights:{website_section:{_id:/generics-bulletin/business,name:Business},website_url:/generics-bulletin/business/testing-vigya-DBH2HFA4JJHH3I6INTPLZYLD5I/}}},{_id:5O7INJQELVBNZLF66B5P77ZJBU,canonical_url:/scrip/r-and-d/clinical-trials/fosun-alkros1-inhibitor-shows-1l-promise-in-advanced-nsclc-5O7INJQELVBNZLF66B5P77ZJBU/,content_elements:{},{},{},{},{},{},{},{},{},{},{},{},{},credits:{by:{additional_properties:{original:{}},name:Xu Hu,type:author}},description:{basic:Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.},display_date:2025-12-05T15:03:33.611Z,headlines:{basic:Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC},owner:{sponsored:false},subtype:Article,taxonomy:{primary_section:{_id:/scrip/r-and-d/clinical-trials}},type:story,website_url:/scrip/r-and-d/clinical-trials/fosun-alkros1-inhibitor-shows-1l-promise-in-advanced-nsclc-5O7INJQELVBNZLF66B5P77ZJBU/,websites:{insights:{website_section:{_id:/scrip/r-and-d/clinical-trials,name:Clinical Trials},website_url:/scrip/r-and-d/clinical-trials/fosun-alkros1-inhibitor-shows-1l-promise-in-advanced-nsclc-5O7INJQELVBNZLF66B5P77ZJBU/}}},count:10000,next:8,_id:ee51602cd5ee12046061ba64d388c35c97255b19a332dc0346287e7c9b18b6d1},expires:1768674855809,lastModified:1768674555623},{\feature\:\results-list\,\feedOffset\:0,\feedSize\:8,\includeSections\:\/scrip/podcasts, /pink-sheet/podcasts, /medtech-insight/podcasts, /hbw-insight/podcasts, /generics-bulletin/podcasts, /invivo/podcasts\}:{data:{content_elements:{_id:UEZLL73UQNDRNEUGKSTMSAFZPY,canonical_url:/pink-sheet/podcasts/nancy-tests-new-podcast-template-UEZLL73UQNDRNEUGKSTMSAFZPY/,content_elements:{},{},{},{},{},{},{},credits:{by:{_id:derrick-gingery,additional_properties:{original:{byline:Derrick Gingery}},name:Derrick Gingery,type:author,url:/authors/derrick-gingery}},description:{basic:Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.\r\n},display_date:2025-12-16T13:38:29.713Z,headlines:{basic:Nancy Tests New Podcast Template},owner:{sponsored:false},promo_items:{basic:{_id:RYW7642ZYRLN7P6PWMG5PI7I7Q,auth:{1:fd8c4368d739d59f5ebf880cbca5ca7cad7160a9e5caefd0a68447b742126456},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/RYW7642ZYRLN7P6PWMG5PI7I7Q.png}},subtype:Podcast,taxonomy:{primary_section:{_id:/pink-sheet/podcasts}},type:story,website_url:/pink-sheet/podcasts/nancy-tests-new-podcast-template-UEZLL73UQNDRNEUGKSTMSAFZPY/,websites:{insights:{website_section:{_id:/pink-sheet/podcasts,name:Podcasts},website_url:/pink-sheet/podcasts/nancy-tests-new-podcast-template-UEZLL73UQNDRNEUGKSTMSAFZPY/}}},{_id:ZMOJPDF67BGDTGPHDP5T222TXE,canonical_url:/generics-bulletin/podcasts/podcast-subtype-sample-vigya-ZMOJPDF67BGDTGPHDP5T222TXE/,content_elements:{},{},{},{},{},{},{},credits:{by:{_id:ian-schofield,additional_properties:{original:{byline:Ian Schofield}},name:Ian Schofield,type:author,url:/authors/ian-schofield}},description:{basic:In this weeks episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimers rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab. },display_date:2025-12-16T09:31:23.662Z,headlines:{basic:Podcast subtype sample-vigya},owner:{sponsored:false},promo_items:{basic:{_id:Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q,auth:{1:83067321da81600860bdc1fc05b6d23dd01fb08e648d4706d36780a0a8f5f377},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q.png}},subtype:Podcast,taxonomy:{primary_section:{_id:/generics-bulletin/podcasts}},type:story,website_url:/generics-bulletin/podcasts/podcast-subtype-sample-vigya-ZMOJPDF67BGDTGPHDP5T222TXE/,websites:{insights:{website_section:{_id:/generics-bulletin/podcasts,name:Podcasts},website_url:/generics-bulletin/podcasts/podcast-subtype-sample-vigya-ZMOJPDF67BGDTGPHDP5T222TXE/}}},{_id:QARSICCAUJEU3KLTHHDWFNIO6M,canonical_url:/pink-sheet/podcasts/pink-sheet-podcast-understanding-the-us-fdas-cder-leadership-shuffle-QARSICCAUJEU3KLTHHDWFNIO6M/,content_elements:{},{},{},{},{},credits:{by:{_id:mary-jo-laffler,additional_properties:{original:{byline:Mary Jo Laffler}},name:Mary Jo Laffler,type:author,url:/authors/mary-jo-laffler}},description:{basic:Pink Sheet reporter and editors discuss the likely impacts of Center for Drug Evaluation and Research Director Richard Pazdur’s retirement from the FDA and Tracy Beth Høeg becoming the center’s acting director.},display_date:2025-12-10T03:26:54.241Z,headlines:{basic:Pink Sheet Podcast: Understanding the US FDA’s CDER Leadership Shuffle },owner:{sponsored:false},promo_items:{basic:{_id:Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q,auth:{1:83067321da81600860bdc1fc05b6d23dd01fb08e648d4706d36780a0a8f5f377},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q.png}},subtype:Podcast,taxonomy:{primary_section:{_id:/pink-sheet/podcasts}},type:story,website_url:/pink-sheet/podcasts/pink-sheet-podcast-understanding-the-us-fdas-cder-leadership-shuffle-QARSICCAUJEU3KLTHHDWFNIO6M/,websites:{insights:{website_section:{_id:/pink-sheet/podcasts,name:Podcasts},website_url:/pink-sheet/podcasts/pink-sheet-podcast-understanding-the-us-fdas-cder-leadership-shuffle-QARSICCAUJEU3KLTHHDWFNIO6M/}}},{_id:ADRPK3O2VJET7LRMHH367XHTFE,canonical_url:/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ADRPK3O2VJET7LRMHH367XHTFE/,content_elements:{},{},{},{},{},{},credits:{by:{_id:reed-miller,additional_properties:{original:{byline:Reed Miller}},name:Reed Miller,type:author,url:/authors/reed-miller}},description:{basic:In this weeks episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimers rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab. },display_date:2025-12-09T18:58:33.274Z,headlines:{basic:Quick Listen: Scrip’s Five Must-Know Things},owner:{sponsored:false},promo_items:{basic:{_id:Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q,auth:{1:83067321da81600860bdc1fc05b6d23dd01fb08e648d4706d36780a0a8f5f377},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/Z4VQ3Q7W5JC2TGS5F75BDS6Z3Q.png}},subtype:Podcast,taxonomy:{primary_section:{_id:/scrip/podcasts/scrips-five-must-know-things}},type:story,website_url:/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ADRPK3O2VJET7LRMHH367XHTFE/,websites:{insights:{website_section:{_id:/scrip/podcasts/scrips-five-must-know-things,name:Scrips Five Must-Know Things},website_url:/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ADRPK3O2VJET7LRMHH367XHTFE/}}},{_id:ML5ZTU22SRLRRGY3XMCGK6HUBI,canonical_url:/MT155075/Digital-Health-Roundup-Digital-Therapeutics-Navigate-GLP1-Immersive-Gaming-DHCoE-AI-Framework-Hello-Heart/,content_elements:{},{subtype:soundcloud},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},{},credits:{by:},description:{basic:In this week’s Digital Health Roundup, Medtech Insight’s Ryan Nelson highlights Click Therapeutics’ FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics’ personalized neuromodulation for Alzheimer’s patients. Marion Webb discusses her interview with MindMaze’s John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart’s new symptom-tracking feature in their heart-focused app. },display_date:2025-12-08T07:24:56.354Z,headlines:{basic:Digital Health Roundup: Digital Therapeutics Navigate GLP-1, Immersive Gaming; DHCoE AI Framework; Hello Heart},owner:{sponsored:false},promo_items:{basic:{_id:HW7VBRD5FFP3PGUYPJYBIIASXI,auth:{1:60afb493a6803513d7485edea71d77525122aa258fa8ea5f432399c9b764dfe6},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/HW7VBRD5FFP3PGUYPJYBIIASXI.jpg}},subtype:Podcast,taxonomy:{primary_section:{_id:/medtech-insight/podcasts/digital-health-roundup}},type:story,website_url:/MT155075/Digital-Health-Roundup-Digital-Therapeutics-Navigate-GLP1-Immersive-Gaming-DHCoE-AI-Framework-Hello-Heart/,websites:{insights:{website_section:{_id:/medtech-insight/podcasts/digital-health-roundup,name:Digital Health Roundup},website_url:/MT155075/Digital-Health-Roundup-Digital-Therapeutics-Navigate-GLP1-Immersive-Gaming-DHCoE-AI-Framework-Hello-Heart/}}},{_id:OZXW3LLTCNAPTIIN3PO3VTQ7HI,canonical_url:/medtech-insight/podcasts/digital-health-roundup/free-medtech-insight-podcast-article-without-an-author-OZXW3LLTCNAPTIIN3PO3VTQ7HI/,content_elements:{},{},{},{},{},{},{},{},{},{},description:{basic:\There is no one who loves pain itself, who seeks after it and wants to have it, simply because it is pain...\\r},display_date:2025-11-20T11:48:36.717Z,headlines:{basic:Free Medtech Insight Podcast Article Without An Author},owner:{sponsored:false},promo_items:{basic:{_id:HW7VBRD5FFP3PGUYPJYBIIASXI,auth:{1:60afb493a6803513d7485edea71d77525122aa258fa8ea5f432399c9b764dfe6},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/HW7VBRD5FFP3PGUYPJYBIIASXI.jpg}},subtype:Podcast,taxonomy:{primary_section:{_id:/medtech-insight/podcasts/digital-health-roundup}},type:story,website_url:/medtech-insight/podcasts/digital-health-roundup/free-medtech-insight-podcast-article-without-an-author-OZXW3LLTCNAPTIIN3PO3VTQ7HI/,websites:{insights:{website_section:{_id:/medtech-insight/podcasts/digital-health-roundup,name:Digital Health Roundup},website_url:/medtech-insight/podcasts/digital-health-roundup/free-medtech-insight-podcast-article-without-an-author-OZXW3LLTCNAPTIIN3PO3VTQ7HI/}}},{_id:CI4JISINCJGMLFEYOWX5H6U36U,canonical_url:/generics-bulletin/adhd-CI4JISINCJGMLFEYOWX5H6U36U/,content_elements:{},{},{},{},{},{},{},{},{},{},description:{basic:This is regarding ADHD.},display_date:2025-11-09T18:30:00Z,headlines:{basic:ADHD},owner:{sponsored:false},promo_items:{basic:{_id:767SS7XYKJP7FPHYFPSAEWHZSM,auth:{1:16228c50dc97cdf5cc75ff24a7a98b5838d73d65ce985d937696e00013f00bee},type:image,url:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/767SS7XYKJP7FPHYFPSAEWHZSM.jpg}},taxonomy:{},type:gallery,website_url:/generics-bulletin/adhd-CI4JISINCJGMLFEYOWX5H6U36U/,websites:{insights:{website_section:{_id:/generics-bulletin,name:Generics Bulletin},website_url:/generics-bulletin/adhd-CI4JISINCJGMLFEYOWX5H6U36U/}}},{_id:UQBZ7QICUVDDRH42UPK3KZAMKE,canonical_url:/scrip/xxxx-UQBZ7QICUVDDRH42UPK3KZAMKE/,content_elements:{subtype:soundcloud},{},credits:{by:{_id:saba-afreen,additional_properties:{original:{byline:Saba Afreen}},name:Saba Afreen,type:author,url:/authors/saba-afreenm/}},description:{basic:In this weeks episode: Pfizer’s backroom US pricing deal; confusion over Japan’s pharma tariffs; more direct-to-patient schemes in the US; first approval for Novartis’s remibrutinib; and GSK’s CEO to step down. },display_date:2025-10-21T07:29:40.339Z,headlines:{basic:Quick Listen: Scrip’s Five Must-Know Things},owner:{sponsored:false},subtype:Podcast,taxonomy:{primary_section:{_id:/scrip}},type:story,website_url:/scrip/xxxx-UQBZ7QICUVDDRH42UPK3KZAMKE/,websites:{insights:{website_section:{_id:/scrip,name:Scrip},website_url:/scrip/xxxx-UQBZ7QICUVDDRH42UPK3KZAMKE/}}},count:51,next:8,_id:b64d77187e2eeebe9b9111f8294f46c7276da8eeb7cb2f29a4935834e0f7dedd},expires:1768674855851,lastModified:1768674555620}}};Fusion.layoutright-rail;Fusion.metas{page-type:{value:homepage,html:false},meta namedescription:{value:This is Insights home page meta description,html:true},og:image:{value:https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/XWJL7WGEH5LPBNNARY6RRNCDX4.jpg,html:true},og:title:{value:Manually set title News Context Impact,html:true}};Fusion.outputTypedefault;Fusion.templatepage/pOWhde68hgill5gu;Fusion.tree{collection:layouts,type:right-rail,props:{collection:layouts,type:right-rail,id:right-rail,childProps:{collection:sections,id:0},{collection:sections,id:1},{collection:sections,id:2},{collection:sections,id:3},{collection:sections,id:4},{collection:sections,id:5}},children:{collection:sections,props:{collection:sections,id:0},children:{collection:chains,type:header-nav-chain,props:{collection:chains,type:header-nav-chain,id:c0fRmZ03a1eA1X1,customFields:{hierarchy:main_navigation,logoAlignment:left,showHorizontalSeperatorDots:false,ariaLabel:Sections Menu,ariaLabelLink:,leftComponentMobile1:menu,leftComponentDesktop1:menu,leftComponentDesktop2:none,rightComponentMobile1:custom,rightComponentCustomIndexMobile1:1,rightComponentDesktop1:custom,rightComponentCustomIndexDesktop1:1,rightComponentDesktop2:none,rightComponentCustomIndexDesktop2:null,menuComponentMobile1:queryly,menuComponentMobile2:none,menuComponentCustomIndexMobile2:null,menuComponentDesktop1:queryly,menuComponentCustomIndexDesktop1:1,menuComponentDesktop2:none},displayProperties:{}},children:{collection:features,type:identity/header-acount-action,props:{collection:features,type:identity/header-acount-action,id:f0fAo8IzDoJ77E-0-0-0,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{helpLink:/help,askLink:/ask-the-analyst,contactLink:/contact-us,PDFLink:/pdf-library,myAccLink:/my-account/contact-information/,myViewLink:/my-view-page,trialLink:https://www.citeline.com/en/app-insights-trial,isNewTab:true},displayProperties:{},localEdits:{},variants:{}}}}},{collection:sections,props:{collection:sections,id:1},children:{collection:features,type:@wpmedia/htmlbox-block/htmlbox,props:{collection:features,type:@wpmedia/htmlbox-block/htmlbox,id:f0fIW5bNfAVN1x6,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{HTML:style>\nh1.tagline {\noverflow: hidden;\nposition: absolute;\nheight: 1px;\n}\n/style>\nh1 class\tagline\>Citeline, a Norstella company/h1>},displayProperties:{},localEdits:{},variants:{}}},{collection:features,type:home/html-box,props:{collection:features,type:home/html-box,id:f0fRDvrga1eA1xc,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{HTML:div id\heroContainer\ class\hpsection\>\ndiv class\header-with-divider\>\nh2 class\c-heading\>News. Context. span>Impact./span>/h2>\n/div>\np>In-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries./p>\na class\c-button c-button--link c-button--medium c-button--primary highlight_button button-states\ href\/search/?query*\>span>Search Our Website/span>/a>\n/div>\n\n},displayProperties:{},localEdits:{},variants:{}}},{collection:chains,type:@wpmedia/single-chain-block/single-chain,props:{collection:chains,type:@wpmedia/single-chain-block/single-chain,id:c0fELLymcGFM231,customFields:{},displayProperties:{}},children:{collection:features,type:@wpmedia/htmlbox-block/htmlbox,props:{collection:features,type:@wpmedia/htmlbox-block/htmlbox,id:f0f3gr8zoIru2C,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{HTML:div id\mostRead\ class\hpsection\>\nh2>Recent Articles/h2>\n/div>},displayProperties:{},localEdits:{},variants:{}}},{collection:features,type:article/read-more,props:{collection:features,type:article/read-more,id:f0fbYIHOb1eA1c9,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{listContentConfig:{contentService:story-feed-sections,contentConfigValues:{feedOffset:,feedSize:4,includeSections:/scrip, /medtech-insight, /in-vivo, /pink-sheet, /hbw-insight, /generics-bulletin}},showBookmark:false,showButton:true,showImage:true,showBorder:true,showAuthor:false,columnsToShow:four,rowsToShow:one},displayProperties:{},localEdits:{},variants:{}}}},{collection:features,type:@wpmedia/htmlbox-block/htmlbox,props:{collection:features,type:@wpmedia/htmlbox-block/htmlbox,id:f0fGH15u1FsC66J,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{HTML:div id\mostRead\ class\hpsection\>\nh2>Most Read Articles - TEST two 4x1 CONFIG/h2>\n/div>},displayProperties:{},localEdits:{},variants:{}}},{collection:chains,type:single-chain,props:{collection:chains,type:single-chain,id:c0f4m6LZHMcH6pc,customFields:{background:transparent,gap:1.5rem},displayProperties:{}},children:{collection:features,type:article/read-more,props:{collection:features,type:article/read-more,id:f0fnSJ1DESLD6jW,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{listContentConfig:{contentService:story-feed-sections,contentConfigValues:{feedOffset:,feedSize:4,includeSections:/scrip, /pink-sheet}},showBookmark:false,showButton:false,showImage:true,showBorder:true,showAuthor:false,columnsToShow:four,rowsToShow:one,pbInternal_cloneId:f0fnSJ1DESLD6jW},displayProperties:{},localEdits:{},variants:{}}}},{collection:chains,type:single-chain,props:{collection:chains,type:single-chain,id:c0faal61xnXR1NK,customFields:{background:transparent,gap:1.5rem,pbInternal_cloneId:c0faal61xnXR1NK},displayProperties:{}},children:{collection:features,type:article/read-more,props:{collection:features,type:article/read-more,id:f0fFtURCwnXR1DM,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{listContentConfig:{contentService:story-feed-sections,contentConfigValues:{feedOffset:,feedSize:4,includeSections:/medtech-insight, /in-vivo, /hbw-insight, /generics-bulletin}},showBookmark:false,showButton:false,showImage:true,showBorder:true,showAuthor:false,columnsToShow:four,rowsToShow:one,pbInternal_cloneId:f0fnSJ1DESLD6jW},displayProperties:{},localEdits:{},variants:{}}}},{collection:features,type:@wpmedia/htmlbox-block/htmlbox,props:{collection:features,type:@wpmedia/htmlbox-block/htmlbox,id:f0fn3LRbvMj853H,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{HTML:div id\mostRead\ class\hpsection\>\nh2>Citeline Podcasts/h2>\n/div>,pbInternal_cloneId:f0fn3LRbvMj853H},displayProperties:{},localEdits:{},variants:{}}},{collection:chains,type:single-chain,props:{collection:chains,type:single-chain,id:c0flcJsHwcI85Ro,customFields:{background:transparent,gap:1.5rem,pbInternal_cloneId:c0flcJsHwcI85Ro},displayProperties:{}},children:{collection:features,type:article/read-more,props:{collection:features,type:article/read-more,id:f0foMQMewcI85ni,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{listContentConfig:{contentService:story-feed-sections,contentConfigValues:{feedOffset:,feedSize:4,includeSections:/scrip/podcasts, /pink-sheet/podcasts, /medtech-insight/podcasts, /hbw-insight/podcasts, /generics-bulletin/podcasts, /invivo/podcasts}},showBookmark:false,showButton:false,showImage:true,showBorder:true,showAuthor:false,columnsToShow:four,rowsToShow:one,pbInternal_cloneId:f0fnSJ1DESLD6jW},displayProperties:{},localEdits:{},variants:{}}}},{collection:features,type:home/html-box,props:{collection:features,type:home/html-box,id:f0foupGIwuKZ16V,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{HTML:div id\quoteContainer\ class\hpsection\>\n\ndiv class\slideshow-container\>\ndiv class\quote-block__quote-mark\>/div>\ndiv class\mySlides fade\>\n  div class\text\>strong>Scrip/strong>\nis an invaluable source of information and insight about key developments in the biopharmaceutical industry. It has produced some of the most detailed reporting about emerging therapeutics in our field (the liver disease nonalcoholic steatohepatitis), with crisp perspective on scientific, business and regulatory dynamics./div>\np>strong>Chris Frates/strong>, VP of Corporate Communications and Patient Advocacybr>span>Madrigal Pharmaceuticals/span>/p>\n/div>\n\ndiv class\mySlides fade\>\n  div class\text\>Ive been reading\nstrong>Generics Bulletin/strong> for over a decade now and it is really of great help to understand the latest news related to generics and biosimilars, including Licensing and M&A deals as well as new Authorities regulations./div>\np>strong>Alex Falgas/strong>, Global SVP - BD Portfolio & Strategybr>span>Corporate Europe & MENA, Accord Healthcare/span>/p>\n/div>\n\ndiv class\mySlides fade\>\n  div class\text\>strong>Medtech Insight/strong>\nis my go-to source for everything medical devices in the EU and UK. Medtech Insight not only provides timely updates but also analysis that provides insight beyond mere description/div>\np>strong>Johan Ordish/strong>, Head of Digital Health and Innovation Policybr>span>Roche Diagnostics/span>/p>\n/div>\n\n/div>\nbr>\n\ndiv style\text-align:center\>\n  span class\dot\>/span> \n  span class\dot\>/span> \n  span class\dot\>/span> \n/div>\n\n/div>\n\n},displayProperties:{},localEdits:{},variants:{}}},{collection:features,type:home/html-box,props:{collection:features,type:home/html-box,id:f0fIheIfGPhj1o0,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{HTML:script>\nlet slideIndex  0;\nshowSlides();\n\nfunction showSlides() {\n  let i;\n  let slides  document.getElementsByClassName(\mySlides\);\n  let dots  document.getElementsByClassName(\dot\);\n  for (i  0; i  slides.length; i++) {\n    slidesi.style.display  \none\;  \n  }\n  slideIndex++;\n  if (slideIndex > slides.length) {slideIndex  1}    \n  for (i  0; i  dots.length; i++) {\n    dotsi.className  dotsi.className.replace(\ active\, \\);\n  }\n  slidesslideIndex-1.style.display  \block\;  \n  dotsslideIndex-1.className + \ active\;\n  setTimeout(showSlides, 7000); // Change image every 7 seconds\n}\n\/script>},displayProperties:{},localEdits:{},variants:{}}},{collection:features,type:home/html-box,props:{collection:features,type:home/html-box,id:f0fgoJT0iyRJ2PM,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{HTML:div id\ourPubs\ class\hpsection\>\nh2>Our Publications/h2>\np>A comprehensive and dependable information source aimed at ensuring industry leaders can stay on top of the latest regulatory, legal, market and commercial developments to anticipate potential threats and identify new opportunities./p>\n\ndiv class\pubContainer\>\n\na class\pubcards-link\ href\/pink-sheet\>\ndiv class\card\>\n  img src\https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/H3276TUFFJMXLHNWTJMIOPLHOQ.jpg\ alt\Pink Sheet\ loading\lazy\ width\340\ height\204\>\n  div class\cardContainer\>\n    h3>Regulatory & Policy/h3>\n    p>Essential updates and comprehensive coverage of industry regulations and emerging policy trends./p>\n  /div>\n/div>\n/a>\n\na class\pubcards-link\ href\/scrip\>\ndiv class\card\>\n  img src\https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/PJWNZDT72JLOVP4VL2ZEFCUB64.jpg\ alt\Scrip\ loading\lazy\ width\340\ height\204\>\n  div class\cardContainer\>\n    h3>Commercial Insights/h3>\n    p>In-depth analysis of the global biopharma industry, offering news that goes beyond the headlines./p>\n  /div>\n/div>\n/a>\n\na class\pubcards-link\ href\/in-vivo\>\ndiv class\card\>\n  img src\https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/25NBFOMSIJKN3DR6PDRFZWDCVU.jpg\ alt\In Vivo\  loading\lazy\ width\340\ height\204\>\n  div class\cardContainer\>\n    h3>Executive Perspectives/h3>\n    p>Exclusive interviews, expert opinion, and critical insights tailored for life science decision-makers./p>\n  /div>\n/div>\n/a>\n\na class\pubcards-link\ href\/medtech-insight\>\ndiv class\card\>\n  img src\https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/ZM6WHG6WIBIEXNMFJN7XUJAFSA.jpg\ alt\Medtech Insight\ loading\lazy\ width\340\ height\204\>\n  div class\cardContainer\>\n    h3>Medical Technology/h3>\n    p>Contextualized reporting on medtech advancements, market dynamics, industry data, and expert insights./p>\n  /div>\n/div>\n/a>\n\na class\pubcards-link\ href\/generics-bulletin\>\ndiv class\card\>\n  img src\https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/5DMQHL7EKZNITECAZSZHMZOHL4.jpg\ alt\Avatar\ loading\lazy\ width\340\ height\204\>\n  div class\cardContainer\>\n    h3>Off-Patent Medicines/h3>\n    p>Unrivalled news and analysis of the global generic, biosimilars and value-added medicines industries./p>\n  /div>\n/div>\n/a>\n\na class\pubcards-link\ href\/hbw-insight\>\ndiv class\card\>\n  img src\https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/5QRXNUACWJPKHB6LA2JAETGVSM.jpg\ alt\HBW Insight\ loading\lazy\ width\340\ height\204\>\n  div class\cardContainer\>\n    h3>Health & Wellness/h3>\n    p>Your primary source for impactful news and insights in the health, beauty, and wellness industries./p>\n  /div>\n/div>\n/a>\n\n\n\n/div>\n\n/div>},displayProperties:{},localEdits:{},variants:{}}},{collection:features,type:home/html-box,props:{collection:features,type:home/html-box,id:f0f3iIbuGVZTMg,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{HTML:div id\depthAnalysis\ class\hpsection\>\ndiv class\fifty-fifty__container \>\ndiv class\fifty-fifty__image-wrapper\>\nimg src\https://www.citeline.com/-/media/citeline/product-services/commercialization/generic-bulletin/50-50.png\ class\fifty-fifty__image\ alt\In Depth Industry Analysis\>\n/div>\ndiv class\fifty-fifty__content\>\nh2 style\text-align:left;\>In-Depth Industry Analysis/h2>\ndiv class\fifty-fifty__content-body rich-text-block\>\np>A comprehensive and dependable information source aimed at ensuring industry leaders can stay on top of the latest regulatory, legal, market and commercial developments to anticipate potential threats and identify new opportunities./p>\np>Analysis and opinion covers key topic areas such as:/p>\nul>\n    li>regulatory and compliance changes/li>\n    li>legal and legislations advances/li>\n    li>competitive developments/li>\n    li>merger and acquisition activities/li>\n    li>new product launches/li>\n/ul>\n\t\t\t/div>\n\t\t/div>\n\t/div>\n/div>},displayProperties:{},localEdits:{},variants:{}}},{collection:features,type:@wpmedia/htmlbox-block/htmlbox,props:{collection:features,type:@wpmedia/htmlbox-block/htmlbox,id:f0fJBQH3CmQ33Bn,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{HTML:div class\fig_desc_container\>\ndiv class\fig_desc\>\np class\figure\>400/p>\np class\fig_description\>Articles/p>\n/div>\ndiv class\fig_desc\>p class\figure\>50/p>p class\fig_description\>Podcasts/p>/div>div class\fig_desc\>p class\figure\>100/p>p class\fig_description\>Analysis/p>/div>div class\fig_desc\>p class\figure\>20/p>p class\fig_description\>Conference Coverage/p>/div>/div>},displayProperties:{},localEdits:{},variants:{}}},{collection:features,type:home/html-box,props:{collection:features,type:home/html-box,id:f0fzD3RmPgfXGe,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{HTML:div id\mobileApp\ class\section\>\ndiv class\container\>\ndiv>\nimg src\https://cloudfront-us-east-1.images.arcpublishing.com/sandbox.norstella/34LNQC5ISBCHPDTNVK2IETDJHY.png\ alt\Citeline app\>\n/div>\ndiv>\np>Sign up today andbr> see for yourself how we can help./p>\na class\c-button c-button--link c-button--medium c-button--primary highlight_button button-states\ href\https://www.citeline.com/en/products-services/commercialization/citeline-news-and-insights-app\ target\_blank\>span>Download App/span>/a>\n/div>\n/div>\n/div>\n/div>},displayProperties:{},localEdits:{},variants:{}}},{collection:features,type:home/html-box,props:{collection:features,type:home/html-box,id:f0fY6aB9ToFa12c,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{HTML:div id\meetTeam\ class\hpsection\>\n  h2>Meet The Team/h2>\n  br>\n  div class\container\>\n    div>\n      img\n        src\https://cloudfront-us-east-1.images.arcpublishing.com/norstella/3UCAMJEUPBCF3AU354OIP3PBSM.png\\n        style\width:200px;height:200px;object-fit:cover;\\n        width\200\ height\200\\n        alt\Karen Coleman\ loading\lazy\>\n      p class\name\>Karen Coleman/p>\n      p class\title\>Executive Director,br> News and Insights/p>\n    /div>\n\n    div>\n      img\n        src\https://cloudfront-us-east-1.images.arcpublishing.com/norstella/3ARRTK6C5ZEDZKNG3H4PPIDBFE.png\\n        style\width:200px;height:200px;object-fit:cover;\\n        width\200\ height\200\\n        alt\Ian Haydock\ loading\lazy\>\n      p class\name\>Ian Haydock/p>\n      p class\title\>Editor-in-Chief,br> APAC/p>\n    /div>\n\n    div>\n      img\n        src\https://cloudfront-us-east-1.images.arcpublishing.com/norstella/DBHW25RDPJGBJFHC6ST3CB27VM.png\\n        style\width:200px;height:200px;object-fit:cover;\\n        width\200\ height\200\\n        alt\Matt Hobbs\ loading\lazy\>\n      p class\name\>Nielsen Hobbs/p>\n      p class\title\>Interim Editor-in-Chief,br> em>Pink Sheet/em>/p>\n    /div>\n\n    div>\n      img\n        src\https://cloudfront-us-east-1.images.arcpublishing.com/norstella/5BJDPWIWFZFZTPAUXNVRL25BPM.png\\n        style\width:200px;height:200px;object-fit:cover;\\n        width\200\ height\200\\n        alt\Eleanor Malone\ loading\lazy\>\n      p class\name\>Eleanor Malone/p>\n      p class\title\>Editor-in-Chief,br> Commercial Insights/p>\n    /div>\n\n    div>\n      img\n        src\https://cloudfront-us-east-1.images.arcpublishing.com/norstella/BJSNON6BXFCXXB6PBNU5RHO4RA.png\\n        style\width:200px;height:200px;object-fit:cover;\\n        width\200\ height\200\\n        alt\Ryan Nelson\ loading\lazy\>\n      p class\name\>Ryan Nelson/p>\n      p class\title\>Editor-in-Chief,br> em>HBW Insight, Medtech Insight/em>/p>\n    /div>\n  /div>\n\n  br>br>\n\n  div style\text-align:center;\>\n    a class\c-button c-button--link c-button--medium c-button--primary highlight_button button-states\ href\/meet-the-team\>\n      span>Meet The Team/span>\n    /a>\n  /div>\n/div>\n},displayProperties:{},localEdits:{},variants:{}}},{collection:features,type:@wpmedia/htmlbox-block/htmlbox,props:{collection:features,type:@wpmedia/htmlbox-block/htmlbox,id:f0fmv5QMmYGX1g6,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{HTML:div id\questionsSection\ class\hpsection\>\nh2>Questions?/h2>\np>Reach out to a href\mailto:#\>emailaddress@emailaddress.com/p>\n/div>},displayProperties:{},localEdits:{},variants:{}}},{collection:features,type:home/html-box,props:{collection:features,type:home/html-box,id:f0f0M8iwa1eA1zw,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{HTML:style>\n  .c-stack.b-right-rail__full-width-1  {\n  background: #f2f2f2;\n  overflow: hidden;\n  margin-top: -50px;\n  max-inline-size: none;\n  }\n  .c-stack.b-right-rail__full-width-1 .c-stack.b-single-chain {\n  margin: 0 auto;\n  overflow: hidden;\n  }\n\n.c-stack.b-right-rail__full-width-1 .c-stack.b-single-chain {\n}\n\n.full-width2-container {\ndisplay: none;\n}\n\n.b-right-rail__footer {\nmargin-top: -5rem;\n}\n\n\n/* Top Section */\n\n  #heroContainer {\n  font-family:lexend,arial,sans-serif;\n  margin-top: 2rem;\n  text-align: center;\nmargin: -1rem -3rem;\nbackground-color: var(--global-navy);\n  }\n  #heroContainer .c-heading span {\n  background-color: #8700c3;\n  padding: .1rem .7rem;\n  border-radius: 3rem;\n  line-height: 1.7;\ncolor: white;\n  }\n  #heroContainer p {\n  margin: 1rem 0;\n  }\n#heroContainer h2 {\nfont-size: 34px;\n}\n  .navy-heading {\n  color: var(--global-navy);\n  font-weight: bold !important;\n  }\n  .b-search-results-list {\n  width:730px;\n  }\n  .hpsection {\n  padding: 3rem;\n  font-family: lexend, poppins, arial, sans-serif;\n  color: white;\n  }\n  .hpsection h2 {\n  font-size: var(--global-font-size-9);\n  text-align: center;\nmargin-bottom:1rem;\n  }\n  .header-with-divider {\n  text-align: center;\n  color: white;\n  }\n  .c-stack.b-single-chain:nth-child(2) {\n      background-color: white;\n      padding: 2rem;\n  }\n  div.section {\n  font-family: lexend, poppins,arial,sans-serif;\n  }\n\n/* Latest Content Section */\n\n#mostRead {\npadding: 0;\ncolor: var(--global-navy);\n}\n  \n  /* Our Publications Section */\n\n  #ourPubs {\n  background-color: white;\n  text-align: center;\npadding: 3rem 6rem;\n    margin: 0 -1rem;\n    overflow: auto;\nbackground: url(https://www.citeline.com/dist/images/insights-events-bg.png) no-repeat fixed 50% / cover;\n  }\n\n#ourPubs h2 {\ncolor: white;\n}\n\n#ourPubs p {\nmax-width: 1200px;\nmargin: 0 auto;\n}\n  \n  .pubContainer {\n  display: flex;\n  flex-wrap: wrap;\n  justify-content: center;\nmargin: 2rem auto;\nmax-width: 1200px;\n  }\n  \n  a.pubcards-link {\n      color: navy;\n      text-decoration: none;\n     grid-auto-flow: column;\n   display: -ms-grid;\n    display: grid; \n  }\n  \n  .card {\n    transition: 0.3s;\n  background-color: #f2f2f2;\n  width: 340px;\n  border-radius: .625rem;\nmargin: 1.5rem .5rem;\ntext-align: left;\nfont-weight: 300;\nfont-size: 18px;\n  }\n  \n  .card:hover {\n    box-shadow: 0 8px 16px 0 rgba(0,0,0,0.2);\n  }\n  \n  .cardContainer {\n    padding: 1rem 1.5rem;\n  }\n\n  .card img {\n    object-fit: cover;\n    height: 12.75rem;\nborder-top-left-radius: .625rem;\nborder-top-right-radius: .625rem;\n  }\n\n.card h3 {\nfont-size: 20px;\n}\n  \n\n  \n  /* Quote Section */ \n  \n  #quoteContainer {\n  background-color: white;\n      margin: 0 -3rem -5rem -3rem;\ncolor: #000;\n  }\n  \n.quote-block__quote-mark {\n    font-size: 5.625rem;\n    line-height: 1;\n    position: relative;\n    top: -5rem;\n    left: -2rem;\n}\n\n.quote-block__quote-mark:before {\n    content: \“\;\n    display: block;\n    color: #8700c3;\n}\n\n.mySlides {display: none;}\n\n.mySlides p {\nmargin-top: 22px;\nfont-size:18px;\n}\n\n.mySlides p span {\ncolor: #8700c3;\n}\n\n.slideshow-container {\npadding: 3rem;\nmargin: 0 auto;\nheight: 250px;\nfont-size: 1.5rem;\ndisplay: flex;\nalign-items: center;\nwidth:1200px;\n}\n\n.dot {\n  cursor: pointer;\n  height: 15px;\n  width: 15px;\n  margin: 0 2px;\n  background-color: #bbb;\n  border-radius: 50%;\n  display: inline-block;\n  transition: background-color 0.6s ease;\n}\n\n.active, .dot:hover {\n  background-color: #717171;\n}\n\n/* Fading animation */\n.fade {\n  animation-name: fade;\n  animation-duration: 1.5s;\n}\n\n@keyframes fade {\n  from {opacity: .4} \n  to {opacity: 1}\n}\n\n/* On smaller screens, decrease text size */\n@media only screen and (max-width: 300px) {\n  .text {font-size: 11px}\n}\n  \n/* In Depth Analysis Section */\n\n#depthAnalysis {\nbackground-color: var(--global-navy);\nmargin: -3rem;\n}\n.fifty-fifty__container {\n    margin-left: auto;\n    margin-right: auto;\n    max-width: 69.5rem;\n    display: flex;\n    justify-content: center;\n    gap: 1.25rem;\ncolor: white;\n\n}\n\n.fifty-fifty__image-wrapper {\n    flex: 1 0 0;\n    width: 100%;\n    position: relative;\n}\n\n.fifty-fifty__image {\n    height: 100%;\n    width: 100%;\n    border-radius: .625rem;\n    -o-object-fit: cover;\n    object-fit: cover;\n    -o-object-position: center;\n    object-position: center;\n}\n\n.fifty-fifty__content {\n    flex: 1 0 0;\n    display: flex;\n    flex-direction: column;\n    justify-content: center;\n}\n\n.fifty-fifty__container  ul {\npadding-inline-start: 1rem;\nmargin-top: 1rem;\n}\n.fifty-fifty__container  ul li{margin-bottom:0.5rem!important;}\n   .fifty-fifty__container p:not(.fifty-fifty__content-title) {font-weight:200!important;}\n\n/* Most Read */ \n\n@media (min-width: 76rem) {\n    .read-more-wrapper_four {\nwidth: 1200px;\n}\n}\n\n/* Stats */\n\n.fig_desc_container {\ndisplay: flex;\ncolor: white;\nplace-content: space-evenly;\nmargin: 0 -1rem -3rem;\npadding: 2rem 0 3rem;\nbackground-color: #8800c4;\nflex-wrap: wrap;\n}\n.fig_desc {\nfont-family: lexend,poppins,arial,sans-serif;\nline-height: 1.2;\n}\n.fig_desc .figure {\nfont-size:60px;\nfont-weight:600;\n}\n\n  /* Mobile App Section */\n  \n  .text-and-image, #mobileApp {\n  background-color:white;\n  }\n  #mobileApp {\n  padding: 3rem 6rem;\n      margin: 0 -1rem;\n  }\n  #mobileApp img {\n  width: 250px;\nmargin-right: 2rem;\n  }\n  #mobileApp p {\n  font-size: 30px;\n  margin-bottom: 2rem;\n  }\n#mobileApp .container {\n width:900px;\ndisplay: flex;\nalign-items: center;\nmargin: 0 auto;\n}\n\n\n/* Meet Team Section */\n\n#meetTeam {\nbackground-color: var(--global-navy);\nmargin: 0 -3rem;\n}\n#meetTeam .container {\n    display: flex;\n    align-items: center;\n    text-align: center;\n    gap: 2rem;\nplace-content: center;\nflex-wrap: wrap;\n}\n\n/* Questions Section */\n\n#questionsSection {\nbackground: white;\ncolor: var(--global-navy);\nmargin: -1rem -3rem;\ntext-align: center;\n}\n\n#questionsSection h2 {\ncolor: var(--global-navy);\n}\n\n  /* Responsive */\n@media only screen and (max-width: 1200px) {\n  .pubContainer {\npadding:0;\n}\n.slideshow-container {\nwidth: auto;\nheight: auto;\n}\n#mobileApp div {\nwidth: auto;\n}\n}\n\n  \n  /style>},displayProperties:{},localEdits:{},variants:{}}}},{collection:sections,props:{collection:sections,id:2},children:},{collection:sections,props:{collection:sections,id:3},children:},{collection:sections,props:{collection:sections,id:4},children:},{collection:sections,props:{collection:sections,id:5},children:{collection:features,type:common/footer-block,props:{collection:features,type:common/footer-block,id:f0flxQu0c1eA1Wv,contentConfig:{contentService:,contentConfigValues:{},inherit:true},customFields:{navigationConfig:{contentService:site-service-hierarchy,contentConfigValues:{hierarchy:footer}},youtubeUrl:,linkedinUrl:https://www.linkedin.com/company/citeline/ ,firstText:Terms and Conditions,firstUrl:https://www.citeline.com/en/terms-of-use,secondText:Privacy Policy,secondUrl:https://www.norstella.com/privacy-center/,thirdText:,thirdUrl:,fourthText:,fourthUrl:},displayProperties:{},localEdits:{},variants:{}}}}};Fusion.spafalse;Fusion.spaEnabledfalse;/script>div iddiv-gpt-ad-1-by-1-interstitial>/div>div idmodal-root>/div>/body>/html>

Subdomains

Date	Domain	IP
keystore-api.test.nxp.norstella-labs.com	2025-12-11	54.72.191.205
preferencesapi.test.nxp.norstella-labs.com	2025-08-18	52.17.243.56
nodejs-lambda.rap.test.nxp.norstella-labs.com	2026-01-07	54.217.242.67
searchapi.dev.nxp.norstella-labs.com	2025-03-07	34.255.49.88
web.insights.norstella-labs.com	2026-01-17	23.46.228.49
cand.insights.norstella-labs.com	2026-01-06	23.46.228.8
backstage.sandbox.norstella-labs.com	2024-11-25	99.80.28.177

View on OTX | View on ThreatMiner

Data with thanks to AlienVault OTX, VirusTotal, Malwr and others. [Sitemap]

Domain > web.insights.norstella-labs.com

Is this malicious?

DNS Resolutions

Port 443

Subdomains